000001109354--12-312020FYus-gaap:OtherAssetsCurrentus-gaap:OtherAssetsNoncurrentP3YP1YP8YP8YP9YP8Yus-gaap:OtherLiabilitiesCurrent0.005adjusted LIBOR0.005adjusted USD LIBORP30DP1YP5Y2M12DP5YP3Y3M18DP3Y8M12Dus-gaap:OperatingLeaseRightOfUseAssetP3YP1YP3YP1YP1Yfalse0001109354us-gaap:AllowanceForCreditLossMember2020-01-012020-12-310001109354us-gaap:AllowanceForCreditLossMember2019-01-012019-12-310001109354us-gaap:AllowanceForCreditLossMember2018-01-012018-12-310001109354us-gaap:AllowanceForCreditLossMember2020-12-310001109354us-gaap:AllowanceForCreditLossMember2019-12-310001109354us-gaap:AllowanceForCreditLossMember2018-12-310001109354us-gaap:AllowanceForCreditLossMember2017-12-310001109354brkr:May2019RepurchaseProgramMember2020-01-012020-12-310001109354brkr:May2019RepurchaseProgramMember2019-01-012019-12-310001109354us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2020-12-310001109354brkr:May2019RepurchaseProgramMember2020-12-310001109354brkr:May2019RepurchaseProgramMember2019-05-310001109354us-gaap:TreasuryStockMember2020-01-012020-12-310001109354us-gaap:CommonStockMember2020-01-012020-12-310001109354us-gaap:TreasuryStockMember2019-01-012019-12-310001109354us-gaap:CommonStockMember2019-01-012019-12-310001109354us-gaap:RetainedEarningsMember2020-12-310001109354us-gaap:ParentMember2020-12-310001109354us-gaap:NoncontrollingInterestMember2020-12-310001109354us-gaap:AdditionalPaidInCapitalMember2020-12-310001109354us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001109354us-gaap:RetainedEarningsMember2019-12-310001109354us-gaap:ParentMember2019-12-310001109354us-gaap:NoncontrollingInterestMember2019-12-310001109354us-gaap:AdditionalPaidInCapitalMember2019-12-310001109354us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001109354brkr:RedeemableNoncontrollingInterestMember2019-12-310001109354us-gaap:RetainedEarningsMember2018-12-310001109354us-gaap:ParentMember2018-12-310001109354us-gaap:NoncontrollingInterestMember2018-12-310001109354us-gaap:AdditionalPaidInCapitalMember2018-12-310001109354us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310001109354brkr:RedeemableNoncontrollingInterestMember2018-12-310001109354us-gaap:RetainedEarningsMember2017-12-310001109354us-gaap:ParentMember2017-12-310001109354us-gaap:NoncontrollingInterestMember2017-12-310001109354us-gaap:AdditionalPaidInCapitalMember2017-12-310001109354us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310001109354brkr:RedeemableNoncontrollingInterestMember2017-12-310001109354us-gaap:TreasuryStockMember2020-12-310001109354us-gaap:CommonStockMember2020-12-310001109354us-gaap:TreasuryStockMember2019-12-310001109354us-gaap:CommonStockMember2019-12-310001109354us-gaap:TreasuryStockMember2018-12-310001109354us-gaap:CommonStockMember2018-12-310001109354us-gaap:TreasuryStockMember2017-12-310001109354us-gaap:CommonStockMember2017-12-310001109354us-gaap:EmployeeStockOptionMemberbrkr:IncentiveCompensationPlan2016Member2020-12-310001109354us-gaap:EmployeeStockOptionMemberbrkr:BrukerCorporationStockPlanMember2020-12-310001109354us-gaap:EmployeeStockOptionMember2019-12-310001109354us-gaap:EmployeeStockOptionMemberbrkr:IncentiveCompensationPlan2016Member2020-01-012020-12-310001109354us-gaap:EmployeeStockOptionMemberbrkr:BrukerCorporationStockPlanMember2020-01-012020-12-310001109354us-gaap:EmployeeStockOptionMember2020-12-310001109354brkr:IncentiveCompensationPlan2016Member2020-12-310001109354brkr:BrukerCorporationStockPlanMember2010-05-140001109354us-gaap:RestrictedStockUnitsRSUMemberbrkr:IncentiveCompensationPlan2016Member2020-12-310001109354brkr:UnvestedRestrictedStockUnitsRsuMember2020-12-310001109354brkr:UnvestedRestrictedStockUnitsRsuMember2019-12-310001109354us-gaap:RestrictedStockUnitsRSUMemberbrkr:IncentiveCompensationPlan2016Member2020-01-012020-12-310001109354us-gaap:RestrictedStockMemberbrkr:BrukerCorporationStockPlanMember2020-01-012020-12-310001109354brkr:UnvestedRestrictedStockUnitsRsuMember2020-01-012020-12-310001109354srt:MinimumMemberbrkr:IncentiveCompensationPlan2016Member2020-01-012020-12-310001109354srt:MaximumMemberbrkr:IncentiveCompensationPlan2016Member2020-01-012020-12-310001109354srt:MinimumMemberbrkr:BrukerCorporationStockPlanMember2010-05-142010-05-140001109354srt:MaximumMemberbrkr:BrukerCorporationStockPlanMember2010-05-142010-05-140001109354srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001109354us-gaap:ShippingAndHandlingMember2020-01-012020-12-310001109354us-gaap:ShippingAndHandlingMember2019-01-012019-12-310001109354us-gaap:ShippingAndHandlingMember2018-01-012018-12-310001109354brkr:AcquisitionsIn2019Member2020-01-012020-12-310001109354brkr:AcquisitionsIn2018Member2020-01-012020-12-310001109354brkr:RaveLlcMember2020-01-012020-12-310001109354brkr:CanopyBiosciencesLlcMember2020-01-012020-12-310001109354srt:MinimumMember2020-01-012020-12-310001109354srt:MaximumMember2020-01-012020-12-3100011093542020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerNanoGroupMember2020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerCalidGroupMember2020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerBioSpinGroupMember2020-01-012020-12-310001109354us-gaap:TransferredOverTimeMember2020-01-012020-12-310001109354us-gaap:TransferredAtPointInTimeMember2020-01-012020-12-310001109354us-gaap:IntersegmentEliminationMember2020-01-012020-12-310001109354srt:AsiaPacificMember2020-01-012020-12-310001109354country:US2020-01-012020-12-310001109354brkr:RestOfEuropeMember2020-01-012020-12-310001109354brkr:OtherCountryMember2020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerNanoGroupMember2019-01-012019-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerCalidGroupMember2019-01-012019-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerBioSpinGroupMember2019-01-012019-12-310001109354us-gaap:TransferredOverTimeMember2019-01-012019-12-310001109354us-gaap:TransferredAtPointInTimeMember2019-01-012019-12-310001109354us-gaap:IntersegmentEliminationMember2019-01-012019-12-310001109354srt:AsiaPacificMember2019-01-012019-12-310001109354country:US2019-01-012019-12-310001109354country:DE2019-01-012019-12-310001109354brkr:RestOfEuropeMember2019-01-012019-12-310001109354brkr:OtherCountryMember2019-01-012019-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerNanoGroupMember2018-01-012018-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerCalidGroupMember2018-01-012018-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BrukerBioSpinGroupMember2018-01-012018-12-310001109354us-gaap:TransferredOverTimeMember2018-01-012018-12-310001109354us-gaap:TransferredAtPointInTimeMember2018-01-012018-12-310001109354us-gaap:IntersegmentEliminationMember2018-01-012018-12-310001109354srt:AsiaPacificMember2018-01-012018-12-310001109354country:US2018-01-012018-12-310001109354country:DE2018-01-012018-12-310001109354brkr:RestOfEuropeMember2018-01-012018-12-310001109354brkr:OtherCountryMember2018-01-012018-12-310001109354srt:RestatementAdjustmentMemberus-gaap:AccountingStandardsUpdate201409Member2014-05-310001109354us-gaap:FacilityClosingMember2020-12-310001109354us-gaap:EmployeeSeveranceMember2020-12-310001109354brkr:ProvisionsForExcessInventoryMember2020-12-310001109354us-gaap:FacilityClosingMember2019-12-310001109354us-gaap:EmployeeSeveranceMember2019-12-310001109354brkr:ProvisionsForExcessInventoryMember2019-12-310001109354us-gaap:FacilityClosingMember2018-12-310001109354us-gaap:EmployeeSeveranceMember2018-12-310001109354brkr:ProvisionsForExcessInventoryMember2018-12-310001109354us-gaap:FacilityClosingMember2017-12-310001109354us-gaap:EmployeeSeveranceMember2017-12-310001109354brkr:ProvisionsForExcessInventoryMember2017-12-310001109354us-gaap:OtherExpenseMemberbrkr:OtherRestructuringInitiativesMember2020-01-012020-12-310001109354us-gaap:CostOfSalesMemberbrkr:OtherRestructuringInitiativesMember2020-01-012020-12-310001109354brkr:OtherRestructuringInitiativesMember2020-01-012020-12-310001109354us-gaap:OtherExpenseMemberbrkr:OtherRestructuringInitiativesMember2019-01-012019-12-310001109354us-gaap:CostOfSalesMemberbrkr:OtherRestructuringInitiativesMember2019-01-012019-12-310001109354brkr:OtherRestructuringInitiativesMember2019-01-012019-12-310001109354us-gaap:OtherExpenseMemberbrkr:OtherRestructuringInitiativesMember2018-01-012018-12-310001109354us-gaap:CostOfSalesMemberbrkr:OtherRestructuringInitiativesMember2018-01-012018-12-310001109354brkr:OtherRestructuringInitiativesMember2018-01-012018-12-310001109354srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:ComputerEquipmentMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:BuildingMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:ComputerEquipmentMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:BuildingMember2020-01-012020-12-310001109354us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-01-012020-12-310001109354us-gaap:LandMember2020-12-310001109354brkr:MachineryEquipmentSoftwareAndFurnitureAndFixturesMember2020-12-310001109354brkr:BuildingAndLeaseholdImprovementsMember2020-12-310001109354us-gaap:LandMember2019-12-310001109354brkr:MachineryEquipmentSoftwareAndFurnitureAndFixturesMember2019-12-310001109354brkr:BuildingAndLeaseholdImprovementsMember2019-12-310001109354brkr:LandAndBuildingsAt44ManningRoadMember2020-02-262020-02-260001109354brkr:LandAndBuildingsAt15FortuneDriveMember2020-02-262020-02-2600011093542020-02-262020-02-260001109354brkr:AgapetusGmbhMember2018-12-172018-12-170001109354brkr:MestrelabResearchS.lMember2018-12-042018-12-040001109354brkr:MestrelabResearchS.lMember2018-10-012018-10-010001109354us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310001109354us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310001109354us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-12-310001109354us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310001109354us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMember2020-12-310001109354us-gaap:ForeignCountryMemberbrkr:OtherForeignCountryMember2020-12-310001109354us-gaap:StateAndLocalJurisdictionMember2020-12-310001109354us-gaap:AccountingStandardsUpdate201602Member2019-01-010001109354us-gaap:OperatingSegmentsMemberbrkr:ScientificInstrumentsMember2020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:EnergyAndSuperconTechnologiesMember2020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BsiNanoMember2020-01-012020-12-310001109354brkr:CorporateReconcilingItemsAndEliminationsMember2020-01-012020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:ScientificInstrumentsMember2019-01-012019-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:EnergyAndSuperconTechnologiesMember2019-01-012019-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BsiNanoMember2019-01-012019-12-310001109354brkr:CorporateReconcilingItemsAndEliminationsMember2019-01-012019-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:ScientificInstrumentsMember2018-01-012018-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:EnergyAndSuperconTechnologiesMember2018-01-012018-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:BsiNanoMember2018-01-012018-12-310001109354brkr:CorporateReconcilingItemsAndEliminationsMember2018-01-012018-12-310001109354srt:AsiaPacificMember2020-12-310001109354country:US2020-12-310001109354country:DE2020-12-310001109354brkr:RestOfEuropeMember2020-12-310001109354brkr:OtherCountryMember2020-12-310001109354srt:AsiaPacificMember2019-12-310001109354country:US2019-12-310001109354country:DE2019-12-310001109354brkr:RestOfEuropeMember2019-12-310001109354brkr:OtherCountryMember2019-12-310001109354srt:AsiaPacificMember2018-12-310001109354country:US2018-12-310001109354country:DE2018-12-310001109354brkr:RestOfEuropeMember2018-12-310001109354brkr:OtherCountryMember2018-12-310001109354brkr:Seniornotes3.74PercentSeries2012aTrancheBDueJanuary2019Member2019-01-182019-01-180001109354brkr:SeniorNotes3.16PercentSeries2012aTrancheDueJanuary2017Member2017-01-182017-01-1800011093542020-07-082020-07-080001109354brkr:CapitalLeaseObligationsAndOtherLoanMember2020-12-310001109354brkr:CapitalLeaseObligationsAndOtherLoanMember2019-12-310001109354brkr:TermLoanAgreementMember2019-12-110001109354brkr:RevolvingCreditAgreement2019Member2019-12-110001109354brkr:UnitedStatesDollarRevolvingLoanUnder2015CreditAgreementMember2015-10-270001109354us-gaap:LineOfCreditMember2020-12-310001109354us-gaap:LineOfCreditMember2019-12-310001109354srt:RestatementAdjustmentMemberus-gaap:AccountingStandardsUpdate201409Member2014-05-012014-05-310001109354brkr:ScientificInstrumentsMember2020-12-310001109354brkr:EnergyAndSuperconTechnologiesMember2020-12-310001109354brkr:BsiNanoMember2020-12-310001109354brkr:ScientificInstrumentsMember2019-12-310001109354brkr:EnergyAndSuperconTechnologiesMember2019-12-310001109354brkr:BsiNanoMember2019-12-310001109354brkr:ScientificInstrumentsMember2018-12-310001109354brkr:BsiNanoMember2018-12-310001109354brkr:ScientificInstrumentsMember2017-12-310001109354brkr:BsiNanoMember2017-12-310001109354srt:MinimumMemberus-gaap:TradeNamesMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-310001109354srt:MinimumMemberus-gaap:CustomerRelatedIntangibleAssetsMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:TradeNamesMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-310001109354srt:MaximumMemberus-gaap:CustomerRelatedIntangibleAssetsMember2020-01-012020-12-310001109354us-gaap:TradeNamesMember2020-12-310001109354us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-310001109354us-gaap:OtherIntangibleAssetsMember2020-12-310001109354us-gaap:CustomerRelationshipsMember2020-12-310001109354us-gaap:TradeNamesMember2019-12-310001109354us-gaap:TechnologyBasedIntangibleAssetsMember2019-12-310001109354us-gaap:OtherIntangibleAssetsMember2019-12-310001109354us-gaap:NoncompeteAgreementsMember2019-12-310001109354us-gaap:CustomerRelationshipsMember2019-12-310001109354us-gaap:HybridInstrumentMember2020-12-310001109354brkr:ContingentConsiderationMember2020-12-310001109354us-gaap:HybridInstrumentMember2019-12-310001109354brkr:ContingentConsiderationMember2019-12-310001109354us-gaap:HybridInstrumentMember2018-12-310001109354brkr:ContingentConsiderationMember2018-12-310001109354us-gaap:HybridInstrumentMember2019-01-012019-12-310001109354brkr:HainLifescienceGmbhMember2018-10-150001109354brkr:MestrelabResearchS.lMember2018-10-010001109354brkr:GermanyAndSwitzerlandMember2020-01-012020-12-310001109354country:DE2020-01-012020-12-310001109354country:CH2020-01-012020-12-310001109354us-gaap:CommodityContractMember2020-12-310001109354brkr:U.s.ToSwissFrancCrossCurrencyAndInterestRateSwapAgreementsMember2020-12-310001109354brkr:U.s.ToEuroCrossCurrencyAndInterestRateSwapAgreementsMember2020-12-310001109354us-gaap:CommodityContractMember2019-12-310001109354brkr:U.s.ToSwissFrancCrossCurrencyAndInterestRateSwapAgreementsMember2019-12-310001109354brkr:U.s.ToEuroCrossCurrencyAndInterestRateSwapAgreementsMember2019-12-310001109354us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-12-310001109354us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001109354us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001109354us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310001109354us-gaap:OtherCurrentLiabilitiesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310001109354us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001109354us-gaap:CurrencySwapMember2020-12-310001109354us-gaap:CurrencySwapMember2019-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember2020-01-012020-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2020-01-012020-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember2020-01-012020-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2020-01-012020-12-310001109354us-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:InterestIncomeMember2020-01-012020-12-310001109354us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:InterestIncomeMember2020-01-012020-12-310001109354us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310001109354us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310001109354us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-01-012020-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember2019-01-012019-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestIncomeMember2019-01-012019-12-310001109354brkr:CrossCurrencyAndInterestRateSwapAgreementsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember2019-01-012019-12-310001109354us-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:InterestIncomeMember2019-01-012019-12-310001109354us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-12-310001109354us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-12-310001109354us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-01-012019-12-310001109354us-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:InterestIncomeMember2018-01-012018-12-310001109354us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:InterestIncomeMember2018-01-012018-12-310001109354us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2018-01-012018-12-310001109354us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-12-310001109354us-gaap:ForeignExchangeContractMember2020-12-310001109354us-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001109354us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310001109354us-gaap:ForeignExchangeContractMember2019-12-310001109354us-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:CommodityContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2020-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:CommodityContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2019-12-310001109354us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001109354us-gaap:ForeignExchangeForwardMember2020-12-310001109354us-gaap:ForeignExchangeForwardMember2019-12-310001109354us-gaap:CorporateMember2020-01-012020-12-310001109354brkr:ScientificInstrumentsMember2020-01-012020-12-310001109354brkr:EnergyAndSuperconTechnologiesMember2020-01-012020-12-310001109354brkr:BsiNanoMember2020-01-012020-12-310001109354us-gaap:CorporateMember2019-01-012019-12-310001109354brkr:ScientificInstrumentsMember2019-01-012019-12-310001109354brkr:EnergyAndSuperconTechnologiesMember2019-01-012019-12-310001109354brkr:BsiNanoMember2019-01-012019-12-310001109354us-gaap:CorporateMember2018-01-012018-12-310001109354brkr:ScientificInstrumentsMember2018-01-012018-12-310001109354brkr:EnergyAndSuperconTechnologiesMember2018-01-012018-12-310001109354brkr:BsiNanoMember2018-01-012018-12-310001109354us-gaap:DefinedBenefitPlanEquitySecuritiesMember2020-12-310001109354us-gaap:DefinedBenefitPlanCashMember2020-12-310001109354brkr:RealEstateAndMortgagesMember2020-12-310001109354brkr:BondsIncludingCashMember2020-12-310001109354brkr:SwissLifeCollectiveBvgFoundationMemberus-gaap:FairValueInputsLevel2Member2020-12-310001109354brkr:GroupBpceLifeMemberus-gaap:FairValueInputsLevel2Member2020-12-310001109354us-gaap:FairValueInputsLevel2Member2020-12-310001109354brkr:SwissLifeCollectiveBvgFoundationMember2020-12-310001109354brkr:GroupBpceLifeMember2020-12-310001109354brkr:SwissLifeCollectiveBvgFoundationMemberus-gaap:FairValueInputsLevel2Member2019-12-310001109354brkr:GroupBpceLifeMemberus-gaap:FairValueInputsLevel2Member2019-12-310001109354us-gaap:FairValueInputsLevel2Member2019-12-310001109354brkr:SwissLifeCollectiveBvgFoundationMember2019-12-310001109354brkr:GroupBpceLifeMember2019-12-310001109354us-gaap:DomesticLineOfCreditMemberbrkr:RevolvingCreditAgreement2019Member2019-12-310001109354brkr:NotePurchaseAgreement2019Member2019-12-110001109354brkr:TermLoanAgreementMember2019-12-112019-12-110001109354brkr:UnitedStatesDollarRevolvingLoanUnder2015CreditAgreementMember2015-10-272015-10-270001109354brkr:SeniorNotes4.46PercentSeries2012aTranchedDueJanuary2024Member2012-01-310001109354brkr:SeniorNotes4.31PercentSeries2012aTranchecDueJanuary2022Member2012-01-310001109354brkr:Seniornotes3.74PercentSeries2012aTrancheBDueJanuary2019Member2012-01-310001109354brkr:SeniorNotes3.16PercentSeries2012aTrancheDueJanuary2017Member2012-01-310001109354brkr:NotePurchaseAgreement2012Member2012-01-310001109354brkr:RevolvingCreditAgreement2019Memberus-gaap:PrimeRateMember2020-01-012020-12-310001109354brkr:RevolvingCreditAgreement2019Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001109354brkr:RevolvingCreditAgreement2019Memberbrkr:AdjustedLondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001109354brkr:TermLoanAgreementMemberus-gaap:PrimeRateMember2019-12-112019-12-110001109354brkr:TermLoanAgreementMemberbrkr:UsdLiborMember2019-12-112019-12-110001109354brkr:TermLoanAgreementMember2020-12-310001109354brkr:NotePurchaseAgreement2019Member2020-12-310001109354brkr:NotePurchaseAgreement2012Member2020-12-310001109354brkr:TermLoanAgreementMember2019-12-310001109354brkr:NotePurchaseAgreement2019Member2019-12-310001109354brkr:NotePurchaseAgreement2012Member2019-12-310001109354srt:MinimumMemberbrkr:RevolvingCreditAgreement2019Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001109354srt:MinimumMemberbrkr:RevolvingCreditAgreement2019Memberus-gaap:BaseRateMember2020-01-012020-12-310001109354srt:MaximumMemberbrkr:RevolvingCreditAgreement2019Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001109354srt:MaximumMemberbrkr:RevolvingCreditAgreement2019Memberus-gaap:BaseRateMember2020-01-012020-12-310001109354brkr:RevolvingCreditAgreement2019Memberbrkr:FederalFundsRateMember2020-01-012020-12-310001109354brkr:AdjustedLondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001109354srt:MinimumMemberbrkr:TermLoanAgreementMemberbrkr:UsdLiborMember2019-12-112019-12-110001109354srt:MinimumMemberbrkr:TermLoanAgreementMemberbrkr:AdjustedLondonInterBankOfferedRateUsdLiborMember2019-12-112019-12-110001109354srt:MaximumMemberbrkr:TermLoanAgreementMemberbrkr:UsdLiborMember2019-12-112019-12-110001109354srt:MaximumMemberbrkr:TermLoanAgreementMemberbrkr:AdjustedLondonInterBankOfferedRateUsdLiborMember2019-12-112019-12-110001109354brkr:TermLoanAgreementMemberbrkr:FederalFundsRateMember2019-12-112019-12-110001109354brkr:TermLoanAgreementMemberbrkr:AdjustedLondonInterBankOfferedRateUsdLiborMember2019-12-112019-12-110001109354us-gaap:AccountingStandardsUpdate201409Memberus-gaap:RetainedEarningsMember2018-12-310001109354us-gaap:AccountingStandardsUpdate201409Memberus-gaap:ParentMember2018-12-310001109354us-gaap:AccountingStandardsUpdate201409Memberus-gaap:NoncontrollingInterestMember2018-12-310001109354us-gaap:AccountingStandardsUpdate201409Member2018-12-310001109354us-gaap:ServiceMember2020-01-012020-12-310001109354us-gaap:ProductMember2020-01-012020-12-310001109354us-gaap:ProductAndServiceOtherMember2020-01-012020-12-310001109354us-gaap:LicenseMember2020-01-012020-12-310001109354us-gaap:ServiceMember2019-01-012019-12-310001109354us-gaap:ProductMember2019-01-012019-12-310001109354us-gaap:ProductAndServiceOtherMember2019-01-012019-12-310001109354us-gaap:LicenseMember2019-01-012019-12-310001109354us-gaap:ServiceMember2018-01-012018-12-310001109354us-gaap:ProductMember2018-01-012018-12-310001109354us-gaap:ProductAndServiceOtherMember2018-01-012018-12-310001109354us-gaap:LicenseMember2018-01-012018-12-3100011093542019-12-312019-12-310001109354us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001109354us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001109354us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001109354us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001109354us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-3100011093542017-12-310001109354brkr:CanopyBiosciencesMemberus-gaap:TradeNamesMember2020-09-100001109354brkr:CanopyBiosciencesMemberus-gaap:TechnologyBasedIntangibleAssetsMember2020-09-100001109354brkr:CanopyBiosciencesMemberus-gaap:OrderOrProductionBacklogMember2020-09-100001109354brkr:CanopyBiosciencesMemberus-gaap:CustomerRelationshipsMember2020-09-100001109354brkr:RaveLlcMemberus-gaap:TradeNamesMember2019-04-020001109354brkr:RaveLlcMemberus-gaap:TechnologyBasedIntangibleAssetsMember2019-04-020001109354brkr:RaveLlcMemberus-gaap:CustomerRelationshipsMember2019-04-020001109354brkr:AgapetusGmbhMemberus-gaap:TradeNamesMemberbrkr:BsiNanoMember2018-12-170001109354brkr:AgapetusGmbhMemberus-gaap:TechnologyBasedIntangibleAssetsMemberbrkr:BsiNanoMember2018-12-170001109354brkr:AgapetusGmbhMemberus-gaap:OrderOrProductionBacklogMemberbrkr:BsiNanoMember2018-12-170001109354brkr:AgapetusGmbhMemberus-gaap:CustomerRelationshipsMemberbrkr:BsiNanoMember2018-12-170001109354brkr:MestrelabResearchS.lMemberus-gaap:TradeNamesMemberbrkr:ScientificInstrumentsMember2018-12-040001109354brkr:MestrelabResearchS.lMemberus-gaap:TechnologyBasedIntangibleAssetsMemberbrkr:ScientificInstrumentsMember2018-12-040001109354brkr:MestrelabResearchS.lMemberus-gaap:CustomerRelationshipsMemberbrkr:ScientificInstrumentsMember2018-12-040001109354brkr:HainLifescienceGmbhMemberus-gaap:TradeNamesMemberbrkr:ScientificInstrumentsMember2018-10-150001109354brkr:HainLifescienceGmbhMemberus-gaap:TechnologyBasedIntangibleAssetsMemberbrkr:ScientificInstrumentsMember2018-10-150001109354brkr:HainLifescienceGmbhMemberus-gaap:CustomerRelationshipsMemberbrkr:ScientificInstrumentsMember2018-10-150001109354brkr:JpkInstrumentsAgMemberus-gaap:TradeNamesMemberbrkr:BsiNanoMember2018-07-110001109354brkr:JpkInstrumentsAgMemberus-gaap:TechnologyBasedIntangibleAssetsMemberbrkr:BsiNanoMember2018-07-110001109354brkr:JpkInstrumentsAgMemberus-gaap:OrderOrProductionBacklogMemberbrkr:BsiNanoMember2018-07-110001109354brkr:JpkInstrumentsAgMemberus-gaap:CustomerRelationshipsMemberbrkr:BsiNanoMember2018-07-110001109354brkr:AnasysInstrumentsCorpMemberus-gaap:TradeNamesMemberbrkr:BsiNanoMember2018-04-080001109354brkr:AnasysInstrumentsCorpMemberus-gaap:TechnologyBasedIntangibleAssetsMemberbrkr:BsiNanoMember2018-04-080001109354brkr:AnasysInstrumentsCorpMemberus-gaap:OrderOrProductionBacklogMemberbrkr:BsiNanoMember2018-04-080001109354brkr:AnasysInstrumentsCorpMemberus-gaap:CustomerRelationshipsMemberbrkr:BsiNanoMember2018-04-080001109354brkr:RaveLlcMember2020-12-310001109354brkr:AnasysInstrumentsCorpMember2018-04-082018-04-080001109354brkr:IntegratedProteomicsApplicationsIncMemberbrkr:ScientificInstrumentsMember2020-08-072020-08-070001109354brkr:SmartTipB.v.Memberbrkr:BsiNanoMember2020-04-012020-04-010001109354brkr:HainLifescienceGmbhMember2020-01-312020-01-310001109354brkr:AcquisitionsIn2020Member2020-01-012020-12-310001109354brkr:BiovendorInstrumentsMemberbrkr:ScientificInstrumentsMember2019-11-012019-11-010001109354brkr:MagnettechGmbhMemberbrkr:ScientificInstrumentsMember2019-10-022019-10-020001109354brkr:PmodTechnologiesGmbhMemberbrkr:ScientificInstrumentsMember2019-07-012019-07-010001109354brkr:AmpegonPptGmbhMemberbrkr:EnergyAndSuperconTechnologiesMember2019-03-072019-03-070001109354brkr:ArxspanLlcMemberbrkr:ScientificInstrumentsMember2019-03-042019-03-040001109354brkr:AcquisitionsIn2019Member2019-01-012019-12-310001109354brkr:AgapetusGmbhMemberbrkr:BsiNanoMember2018-12-172018-12-170001109354brkr:MestrelabResearchS.lMemberbrkr:ScientificInstrumentsMember2018-12-042018-12-040001109354brkr:HainLifescienceGmbhMemberbrkr:ScientificInstrumentsMember2018-10-152018-10-150001109354brkr:JpkInstrumentsAgMemberbrkr:BsiNanoMember2018-07-112018-07-110001109354brkr:AnasysInstrumentsCorpMemberbrkr:BsiNanoMember2018-04-082018-04-080001109354brkr:HainLifescienceGmbhMember2020-01-310001109354brkr:AgapetusGmbhMember2018-12-170001109354brkr:MestrelabResearchS.lMember2018-12-040001109354brkr:HainLifescienceGmbhMember2018-10-150001109354brkr:MestrelabResearchS.lMember2018-10-010001109354brkr:JpkInstrumentsAgMember2018-07-110001109354brkr:AnasysInstrumentsCorpMember2018-04-080001109354us-gaap:OperatingSegmentsMemberbrkr:EnergyAndSuperconTechnologiesMember2020-12-310001109354us-gaap:OperatingSegmentsMember2020-12-310001109354brkr:CorporateReconcilingItemsAndEliminationsMember2020-12-310001109354us-gaap:OperatingSegmentsMemberbrkr:EnergyAndSuperconTechnologiesMember2019-12-310001109354us-gaap:OperatingSegmentsMember2019-12-310001109354brkr:CorporateReconcilingItemsAndEliminationsMember2019-12-310001109354us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001109354brkr:UnvestedRestrictedStockUnitsRsuMember2018-01-012018-12-310001109354us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001109354us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001109354us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001109354us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001109354us-gaap:CostOfSalesMember2020-01-012020-12-310001109354us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001109354us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001109354us-gaap:RestrictedStockMember2019-01-012019-12-310001109354us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001109354us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001109354us-gaap:CostOfSalesMember2019-01-012019-12-310001109354us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-310001109354us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310001109354us-gaap:RestrictedStockMember2018-01-012018-12-310001109354us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310001109354us-gaap:EmployeeStockOptionMember2018-01-012018-12-310001109354us-gaap:CostOfSalesMember2018-01-012018-12-310001109354brkr:MestrelabResearchS.lMember2018-01-012018-12-310001109354us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001109354us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001109354us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001109354brkr:CanopyBiosciencesMemberus-gaap:TradeNamesMember2020-09-102020-09-100001109354brkr:CanopyBiosciencesMemberus-gaap:OrderOrProductionBacklogMember2020-09-102020-09-100001109354brkr:CanopyBiosciencesMemberus-gaap:CustomerRelationshipsMember2020-09-102020-09-100001109354brkr:AgapetusGmbhMemberus-gaap:TradeNamesMember2018-12-172018-12-170001109354brkr:AgapetusGmbhMemberus-gaap:OrderOrProductionBacklogMember2018-12-172018-12-170001109354brkr:AgapetusGmbhMemberus-gaap:DevelopedTechnologyRightsMember2018-12-172018-12-170001109354brkr:AgapetusGmbhMemberus-gaap:CustomerRelationshipsMember2018-12-172018-12-170001109354brkr:MestrelabResearchS.lMemberus-gaap:TradeNamesMember2018-10-012018-10-010001109354brkr:MestrelabResearchS.lMemberus-gaap:DevelopedTechnologyRightsMember2018-10-012018-10-010001109354brkr:MestrelabResearchS.lMemberus-gaap:CustomerRelationshipsMember2018-10-012018-10-010001109354brkr:JpkInstrumentsAgMemberus-gaap:OrderOrProductionBacklogMember2018-07-112018-07-110001109354brkr:JpkInstrumentsAgMemberus-gaap:DevelopedTechnologyRightsMember2018-07-112018-07-110001109354brkr:JpkInstrumentsAgMemberus-gaap:CustomerRelationshipsMember2018-07-112018-07-110001109354brkr:JpkInstrumentsAgMember2018-07-112018-07-110001109354brkr:AnasysInstrumentsCorpMemberus-gaap:TradeNamesMember2018-04-082018-04-080001109354brkr:AnasysInstrumentsCorpMemberus-gaap:OrderOrProductionBacklogMember2018-04-082018-04-0800011093542020-06-3000011093542021-02-250001109354brkr:MestrelabResearchS.lMember2020-01-012020-12-310001109354brkr:HainLifescienceGmbhMember2018-10-152018-10-1500011093542017-01-012017-12-310001109354us-gaap:TreasuryStockMember2018-01-012018-12-310001109354us-gaap:CommonStockMember2018-01-012018-12-310001109354brkr:MestrelabResearchS.lMember2019-01-012019-12-310001109354us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001109354us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001109354us-gaap:FacilityClosingMember2020-01-012020-12-310001109354us-gaap:EmployeeSeveranceMember2020-01-012020-12-310001109354brkr:ProvisionsForExcessInventoryMember2020-01-012020-12-310001109354us-gaap:FacilityClosingMember2019-01-012019-12-310001109354us-gaap:EmployeeSeveranceMember2019-01-012019-12-310001109354brkr:ProvisionsForExcessInventoryMember2019-01-012019-12-310001109354us-gaap:FacilityClosingMember2018-01-012018-12-310001109354us-gaap:EmployeeSeveranceMember2018-01-012018-12-310001109354brkr:ProvisionsForExcessInventoryMember2018-01-012018-12-310001109354srt:MaximumMember2020-01-012020-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001109354us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001109354us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2020-12-310001109354us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2019-12-310001109354us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001109354us-gaap:RetainedEarningsMember2019-01-012019-12-310001109354us-gaap:ParentMember2019-01-012019-12-310001109354us-gaap:NoncontrollingInterestMember2019-01-012019-12-310001109354brkr:RedeemableNoncontrollingInterestMember2019-01-012019-12-310001109354us-gaap:RetainedEarningsMember2018-01-012018-12-310001109354us-gaap:ParentMember2018-01-012018-12-310001109354us-gaap:NoncontrollingInterestMember2018-01-012018-12-310001109354brkr:RevolvingCreditAgreement2019Member2020-01-012020-12-310001109354brkr:RevolvingCreditAgreement2019Member2019-12-112019-12-110001109354brkr:BankGuaranteesAndWorkingCapitalLineMember2019-12-310001109354us-gaap:RetainedEarningsMember2020-01-012020-12-310001109354us-gaap:ParentMember2020-01-012020-12-310001109354brkr:RedeemableNoncontrollingInterestMember2020-01-012020-12-310001109354brkr:RedeemableNoncontrollingInterestMember2018-01-012018-12-310001109354us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001109354us-gaap:FairValueMeasurementsRecurringMember2020-12-310001109354us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001109354us-gaap:FairValueMeasurementsRecurringMember2019-12-310001109354country:KRus-gaap:PendingLitigationMemberbrkr:GovernmentalInvestigationsMember2019-06-012019-06-160001109354us-gaap:HybridInstrumentMember2020-01-012020-12-310001109354brkr:ContingentConsiderationMember2020-01-012020-12-310001109354brkr:ContingentConsiderationMember2019-01-012019-12-310001109354brkr:SwissLifeCollectiveBvgFoundationMember2020-01-012020-12-3100011093542018-12-310001109354srt:MinimumMember2020-12-310001109354srt:MaximumMember2020-12-310001109354srt:MinimumMember2019-12-310001109354srt:MaximumMember2019-12-310001109354srt:MinimumMember2018-12-310001109354srt:MaximumMember2018-12-310001109354srt:MinimumMemberbrkr:NotePurchaseAgreement2012Member2020-01-012020-12-310001109354srt:MaximumMemberbrkr:NotePurchaseAgreement2012Member2020-01-012020-12-310001109354srt:MinimumMemberbrkr:RevolvingCreditAgreement2019Member2020-12-310001109354srt:MaximumMemberbrkr:RevolvingCreditAgreement2019Member2020-12-310001109354brkr:SeniorNotes4.46PercentSeries2012aTranchedDueJanuary2024Member2015-10-270001109354brkr:SeniorNotes4.31PercentSeries2012aTranchecDueJanuary2022Member2015-10-270001109354brkr:NotePurchaseAgreement2012Member2020-01-012020-12-310001109354brkr:NotePurchaseAgreement2019Member2019-12-112019-12-1100011093542020-12-3100011093542019-12-310001109354brkr:CanopyBiosciencesMember2020-09-100001109354brkr:RaveLlcMember2019-04-020001109354brkr:AgapetusGmbhMemberbrkr:BsiNanoMember2018-12-170001109354brkr:MestrelabResearchS.lMemberbrkr:ScientificInstrumentsMember2018-12-040001109354brkr:HainLifescienceGmbhMemberbrkr:ScientificInstrumentsMember2018-10-150001109354brkr:JpkInstrumentsAgMemberbrkr:BsiNanoMember2018-07-110001109354brkr:AnasysInstrumentsCorpMemberbrkr:BsiNanoMember2018-04-080001109354brkr:HainLifescienceGmbhMember2020-12-310001109354brkr:HainLifescienceGmbhMember2022-01-010001109354brkr:CanopyBiosciencesMember2020-09-102020-09-100001109354brkr:RaveLlcMember2019-04-022019-04-0200011093542020-01-012020-12-3100011093542019-01-012019-12-3100011093542018-01-012018-12-31iso4217:USDiso4217:EURxbrli:purexbrli:sharesiso4217:USDxbrli:sharesiso4217:CHFbrkr:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934

For the fiscal year ended December 31, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 000-30833

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
Incorporation or organization)

    

04-3110160
(I.R.S. Employer Identification No.)

40 Manning Road, Billerica, MA
(Address of principal executive offices)

01821
(Zip Code)

Registrant’s telephone number, including area code: (978663-3660

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbols(s)

Name of each exchange on which registered

Common Stock

BRKR

Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer 

Accelerated filer 

Non-accelerated filer 

Smaller reporting company 
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 

The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant as of June 30, 2020 (the last business day of the registrant’s most recently completed second fiscal quarter) was $2,172,541,232 based on the reported last sale price on the Nasdaq Global Select Market. The number of shares of the registrant’s common stock outstanding as of February 25, 2021 was 151,565,334.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the information required by Part III of this report (Items 10, 11, 12, 13 and 14) are incorporated by reference from the registrant’s Definitive Proxy Statement on Schedule 14A for its 2021 Annual Meeting of Stockholders to be filed within 120 days of the close of the registrant’s fiscal year.

Table of Contents

BRUKER CORPORATION

ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

    

Page

Part I

Item 1

Business

3

Item 1A

Risk Factors

19

Item 1B

Unresolved Staff Comments

38

Item 2

Properties

38

Item 3

Legal Proceedings

39

Item 4

Mine Safety Disclosures

40

Part II

Item 5

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

41

Item 6

Reserved

42

Item 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

43

Item 7A

Quantitative and Qualitative Disclosures About Market Risk

62

Item 8

Financial Statements and Supplementary Data

65

Item 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

123

Item 9A

Controls and Procedures

123

Item 9B

Other Information

123

Part III

Item 10

Directors, Executive Officers and Corporate Governance

124

Item 11

Executive Compensation

124

Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

124

Item 13

Certain Relationships and Related Transactions, and Director Independence

125

Item 14

Principal Accountant Fees and Services

125

Part IV

Item 15

Exhibits, Financial Statements and Schedules

126

Item 16

Form 10-K Summary

129

Signatures

130

1

Table of Contents

Any statements contained in this Annual Report on Form 10-K that are not statements of historical fact may be deemed to be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “seek,” “may,” “will,” “intend,” “estimate,” “should,” and similar expressions are intended to identify forward-looking statements. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the impact of the novel coronavirus, COVID-19, on our business and operations, including our implementation of certain cost cutting measures and their impact, our intentions regarding our intellectual property, the impact of government contracts and government regulation, our working capital requirements and sufficiency of cash, our competition, the seasonality of our business, the sufficiency of our facilities, our employee relations, the impact of legal or intellectual property proceedings, the impact of changes to tax and accounting rules and changes in law, our anticipated tax rate, our expectations regarding cash dividends, share repurchases, interest expense, interest rate swap agreements, expenses and capital expenditures, the impact of foreign currency exchange rates and changes in commodity prices, the impact of our restructuring initiatives and our expectations regarding backlog and revenue. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties related to adverse changes in the economic and political conditions in the countries in which we operate, the integration of businesses we have acquired or may acquire in the future, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, changes in governmental regulations, the impact of the COVID-19 coronavirus, intellectual property rights, litigation, exposure to foreign currency fluctuations, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends, climate change and other factors. Many of these factors are described in more detail in this Annual Report on Form 10-K under Item 1A. “Risk Factors” and from time to time in other filings we may make with the Securities and Exchange Commission. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the date of the filing of this report.

References to “we,” “us,” “our,” “management” or the “Company” refer to Bruker Corporation and, in some cases, its subsidiaries, as well as all predecessor entities.

Our principal executive offices are located at 40 Manning Road, Billerica, MA 01821, and our telephone number is (978) 663-3660. Information about Bruker Corporation is available at www.bruker.com. The information on our website is not incorporated by reference into and does not form a part of this report. All trademarks, trade names or copyrights referred to in this report are the property of their respective owners.

2

Table of Contents

PART I

ITEM 1 BUSINESS

Our Business

We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products and solutions address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. Our technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography, triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy, and infrared and Raman molecular spectroscopy technologies. Our product portfolio also includes testing solutions used in microbiology and infectious disease diagnostics, including our MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips and fluorescence-based polymerase chain reaction (PCR) technology for selected infectious disease applications. We develop, manufacture and distribute a range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. We also develop, manufacture and market low temperature superconducting materials and devices based primarily on metallic low temperature superconductors. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, North America and Southeast Asia, and have sales offices located throughout the world.

We originally were incorporated in Massachusetts in February 1991, as Bruker Federal Systems Corporation. In February 2000, we reincorporated in Delaware as Bruker Daltonics Inc. In July 2003, we merged with Bruker AXS Inc., and we were the surviving corporation in that merger. In connection with that merger, we changed our name to Bruker BioSciences Corporation and formed two operating subsidiaries, Bruker Daltonics and Bruker AXS. In July 2006, we acquired Bruker Optics Inc. In February 2008, we acquired the Bruker BioSpin group of companies and changed our name to Bruker Corporation.

Business Segments

We have four operating segments, Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) NANO Segment and Bruker Energy & Supercon Technologies (BEST). We have three reportable segments, BSI Life Science, BSI NANO, and BEST. For financial reporting purposes, the Bruker BioSpin and Bruker CALID Groups are aggregated into the BSI Life Science reportable segment because they have similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.

BSI Life Science Segment

Bruker BioSpin Group

The Bruker BioSpin Group comprises the Bruker Magnetic Resonance, Applied Industrial and Clinical, Preclinical Imaging and Service and Lifecycle Support Divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. Magnetic resonance is a natural phenomenon occurring when a molecule placed in a magnetic field gives off a signature radio frequency. The signature radio frequency is characteristic of the particular molecule and provides a multitude of precise chemical and structural information. Depending on the intended application, we market and sell to our customers an NMR system or an EPR system (each as defined below).

3

Table of Contents

Bruker BioSpin also manufactures and sells single and multiple modality systems using MRI, PET, SPECT, CT and MPI technologies (each as defined below). Bruker BioSpin’s products, which have particular application in structural proteomics, drug discovery, pharmaceutical and biotechnology research and production, and the food and materials science fields, provide customers with the ability to determine the structure, dynamics, and function of specific molecules, such as proteins, and to characterize and determine the composition of mixtures.

The majority of Bruker BioSpin’s customers are academic and government research facilities. Other customers include pharmaceutical and biotechnology companies; chemical, food and beverage, clinical and polymer companies; and nonprofit laboratories.

During 2020, we successfully established a new class of NMR systems, which we refer to as GHz class systems, as a material part of our business. We achieved customer acceptance on three 1.2 GHz systems. We also achieved major technical milestones in the remote monitoring capabilities of our systems, enabling new services like predictive maintenance. During 2020, we launched a number of new products and technologies, including a GxP solution for the Biopharma industry, solutions for high performance and automated solid-state NMR, and a new affordable high-resolution NMR product line.

Bruker BioSpin Group’s instruments are based on the following technology platforms:

NMR—Nuclear magnetic resonance;
EPR—Electron paramagnetic resonance;
MRI—Magnetic resonance imaging;
MPI—Magnetic particle imaging;
PET—Positron emission tomography;
SPECT—Single photon emission tomography; and
CT—Computed tomography.

NMR is a qualitative and quantitative analytical technique that is used to determine the molecular structure and purity of a sample. Molecules are placed in a magnetic field and give off a radio frequency signature that is recorded by a sensitive detector. Analysis software helps to determine the molecular structure of the sample. The NMR technique is used in academia, pharmaceutical, biotechnology, food and beverage and clinical companies, and by other industrial users in life science and material science research.

EPR is a process of absorption of microwave radiation by paramagnetic ions or molecules with at least one unpaired electron that spins in the presence of a static magnetic field. EPR detects unpaired electrons unambiguously, whereas other techniques can only provide indirect evidence of their presence. In addition, EPR can identify the paramagnetic species that are detected, which present information on the molecular structure near the unpaired electron and give insight into dynamic processes such as molecular motions or fluidity. Our EPR instruments are used for a wide range of applications, including advanced materials research, materials analysis and quality control.

MRI is a process of creating an image from the manipulation of hydrogen atoms in a magnetic field. In the presence of an external magnetic field, atoms will align with or against the external magnetic field. Application of a radio frequency causes the atoms to jump between high and low energy states. MRI and magnetic resonance spectroscopy, or MRS, include many methods including diffusion-weighted, perfusion-weighted, molecular imaging and contrast-enhance. MRI offers high resolution morphologic information, as well as functional, metabolic or molecular information. Customers use our MRI systems in pharmaceutical research, including metabolomics, to study a number of diseases, including diabetes, neurology, oncology and cardiovascular disorders.

4

Table of Contents

MPI is a process of creating an image from magnetic particles administered to the body of an animal. The magnetic particles are manipulated in a combination of oscillating magnetic fields exhibiting a field free zone. The response of the particles allows a real time 3D data set acquisition of the whole body of an animal, showing the contrast agent distributing in and flowing through the body. This imaging modality is used to detect cardiovascular disorders.

PET is a process of creating an image from positrons after administration of a positron emitting radionuclide to the body of an animal. Annihilation of the positron produces two photons which show an angle of 180° between them, distinguishing these photons from photons originating from other sources. The PET tracer enriches in certain regions of interest within the body and gains molecular information from the animal in vivo. This has widespread applications, most importantly for oncology, inflammation, neurology and cardiovascular disorders, as well as metabolic disease, drug discovery and bone disease.

SPECT uses a contrast agent containing radionuclides which directly emit single photons. The contrast agent enriches in certain parts of the body of an animal and generates images of the radionuclide distribution in the body. SPECT has widespread application in animal investigations in vivo, most importantly in oncology, neurology and cardiovascular disorders.

CT is a technology based on X-rays which are used to generate a complete 3D data set. The most important applications are tissue sample analysis or non-invasive in vivo animal imaging. CT offers the highest spatial resolution of all preclinical imaging modalities and is especially useful to generate morphological information about the object or animal under investigation. CT is being used in a wide range of preclinical investigations in the fields of bone-orthopedics, cardiology, pulmonology, oncology and metabolism among others.

The Bruker BioSpin Group also offers a range of services, product lifecycle support, scientific software and workflow solutions to customers who use Bruker BioSpin products.

Bruker CALID Group

The Bruker CALID Group comprises the Bruker Daltonics and Bruker Optics Divisions. The Bruker Daltonics Division primarily designs, manufactures and distributes life science mass spectrometry, or MS, instruments that can be integrated and used along with sample preparation or chromatography instruments to design an analytical workflow and mass spectrometry-based and molecular diagnostic solutions for microbiology and infectious disease diagnostics. Bruker CALID’s life science mass spectrometry products are used in research, pharmaceutical and biotechnology development. Bruker CALID’s microbiology and infectious disease solutions are used primarily in the human and veterinary clinical diagnostic and food microbiology settings.

Mass spectrometers are sophisticated devices that measure the mass or weight of a molecule and can provide accurate information on the identity, quantity and primary structure of the molecule. Mass spectrometry-based solutions often combine advanced mass spectrometry instrumentation, automated sampling and sample preparation robots, reagent kits and other disposable products used in conducting tests, or assays, and bioinformatics software. We offer mass spectrometry systems and integrated solutions for applications in multiple existing and emerging life science markets and chemical and applied markets, including expression proteomics, clinical proteomics research, metabolic and peptide biomarker profiling, drug discovery and development, molecular diagnostics research and molecular and systems biology, as well as basic molecular medicine research. Our timsTOF Pro mass spectrometer offers workflow solutions for proteomics research. Our MALDI Biotyper mass spectrometry solution and test kits, DNA test strips and fluorescence-based PCR technologies are designed for in vitro diagnostic (IVD) use in clinical microbiology markets in certain configurations and certain countries, where regulatory approvals have been achieved. In addition to culture-based microbial identification with the MALDI Biotyper platform, the Genotype and Fluorotype molecular diagnostics (MDx) kits enable a culture-free detection and analysis of microbes and viruses directly from patient sample with a special focus on tuberculosis, transplant diagnostics and sexually-transmitted diseases.

5

Table of Contents

Molecular Diagnostics utilize Polymerase Chain Reaction (PCR) assays and systems to provide diagnostic solutions for a number of different disease states, including Respiratory, Mycobacteria (including Tuberculosis), Virology, Safety of Immunocompromised patients, Sexually Transmitted Infections, Gastroenteric Diseases as well as other Microbiology tests. Depending on the assay being used, the technology enables users to ascertain basic identification of a certain infection, distinguish infections which can cause similar symptoms and detect specific microbial resistance, all from a single sample. The GenoType portfolio has been established for over 30 years and has been successful in mycobacteria and tuberculosis detection, differentiation, and identification of antibiotic resistance markers. The portfolio now includes FluoroType®, using fluorescence-based real-time PCR technology, and more recently we have also developed LiquidArray® assays based on melt curve analysis for optimized asymmetrical PCR technology. LiquidArray® uses light-on-off probes, providing a powerful technology to identify a broad number of indicators for different infections or resistance markers from a single sample, providing greater depth of information. We are applying this approach to a new portfolio of syndromic panels in development. As a producer of extraction chemistry and instrumentation alongside integrated thermocyclers, software and a range of assays, Bruker brings complete diagnostic solutions to the Molecular Diagnostics market.

The Bruker Optics Division manufactures and distributes research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. These products are utilized in industry, government and academia for a wide range of applications and solutions for life science, pharmaceutical, food and agricultural analysis, quality control and process analysis applications. Infrared and Raman spectroscopy are widely used in both research and industry as simple, rapid, nondestructive and reliable techniques for applications ranging from basic sample identification and quality control to advanced research. The Bruker Optics Division also utilizes Fourier transform and dispersive Raman measurement techniques on an extensive range of laboratory and process spectrometers. The Bruker Optics Division’s products are complemented by a wide range of sampling accessories and techniques, which include, among others, microanalysis and high-throughput screening to help users find suitable solutions to analyze their samples effectively.

Customers of our Bruker CALID Group include pharmaceutical, biotechnology and diagnostics companies, contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensic laboratories, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals and government departments and agencies.

During 2020, we launched a number of new mass spectrometry-based solutions and additional workflows, including the MALDI-2 post-ionization source available as an option on the timsTOF fleX ESI/MALDI mass spectrometer. In our microbiology and molecular diagnostics markets, we introduced the MALDI Biotyper sirius broadly into the market. In our molecular diagnostics portfolio we launched two assays in the field of respiratory disease testing, primarily covering SARS-CoV 2 testing for the diagnosis of COVID-19 infection. The Fluorotyper-SARS-CoV 2 plus kit allows for a real-time PCR detection of the SARS-CoV 2 virus. It detects two viral genes in parallel as a mechanism for high sensitivity. The additional FluoroType® SARS-CoV-2/Flu/RSV assay is a multiplex real-time PCR kit that detects four viruses of clinical significance causing respiratory disease during the winter season: SARS-CoV 2, influenza A, influenza B and respiratory syncytial virus (RSV). During 2020, the Bruker Optics division launched LUMOS II, a fully automated stand-alone FTIR imaging microscope. LUMOS II provides ultrafast FTIR imaging capabilities based on modern focal plane array (FPA) detector technology. The novel LUMOS II is designed to identify particles, to determine coatings and contaminations, and to reveal the polymeric composition of plastics.

The Bruker CALID Group’s instruments are based on the following technology platforms:

MALDI-TOF—Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, including tandem time-of-flight systems (MALDI-TOF/TOF);
ESI-TOF—Electrospray ionization time-of-flight spectrometry, including tandem mass spectrometry systems based on ESI-quadrupole-TOF mass spectrometry (ESI-Q-q-TOF);

6

Table of Contents

MRMS—Magnetic resonance mass spectrometry, including hybrid systems with a quadrupole front end (Q-q-MRMS);
ITMS—Ion trap mass spectrometry;
GC-MS—Gas chromatography-mass spectrometry systems utilizing triple-quadrupole time-of-flight mass spectrometry;
LC-MS—Liquid chromatography-mass spectrometry systems utilizing triple-quadrupole time-of flight mass spectrometry;
FT-IR—Fourier transform-infrared spectroscopy;
NIR—Near-infrared spectroscopy; and
Raman—Raman spectroscopy.

MALDI-TOF mass spectrometers utilize an ionization process to analyze solid samples using a laser that combines high sample throughput with high mass range and sensitivity. Our MALDI-TOF mass spectrometers are particularly useful for applications in clinical diagnostics, environmental and taxonomical research and food processing and quality control. Specific applications include: oligonucleotide and synthetic polymer analysis; protein identification and quantification; peptide de novo sequencing; determination of post-translational modifications of proteins; interaction proteomics and protein function analysis; drug discovery and development; and fast body fluid and tissue peptide or protein biomarker detection. MALDI mass spectrometry allows users to classify and identify microorganisms quickly and reliably with minimal sample preparation efforts and life cycle costs. Our MALDI Biotyper solution, which serves the clinical microbiology market, enables identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi.

ESI-TOF mass spectrometers utilize an electrospray ionization process to analyze liquid samples. This ionization process, which does not dissociate the molecules, allows for rapid data acquisition and analysis of large biological molecules. ESI-TOF mass spectrometers are particularly useful for: identification, protein analysis and functional complex analysis in proteomics and protein function; molecular identification in metabolomics, natural product and drug metabolite analysis; combinatorial chemistry high throughput screening; and fast liquid chromatography mass spectrometry, or liquid chromatography mass spectrometry (LC-MS), in drug discovery and development.

MRMS systems utilize high-field superconducting magnets to offer the highest resolution, selectivity, and mass accuracy currently achievable in mass spectrometry. Our systems based on this technology often eliminate the need for time-consuming separation techniques in complex mixture analyses. In addition, our systems can fragment molecular ions to perform exact mass analysis on all fragments to determine molecular structure. MRMS systems are particularly useful for: the study of the structure and function of biomolecules, including proteins, DNA and natural products; complex mixture analysis including body fluids or combinatorial libraries; high-throughput proteomics and metabolomics; and top-down proteomics of intact proteins without the need for enzymatic digestion of the proteins prior to analysis. We offer next-generation hybrid MRMS systems that combine a traditional external quadrupole mass selector and hexapole collision cell with a high-performance MRMS for further ion dissociation, top-down proteomics tools and ultra-high resolution detection.

ITMS systems collect all ions simultaneously, which improves sensitivity relative to previous quadrupole mass spectrometers. Ion trap mass spectrometers are particularly useful for sequencing and identification based on peptide structural analysis, quantitative liquid chromatography mass spectrometry, identification of combinatorial libraries and generally enhancing the speed and efficiency of the drug discovery and development process.

7

Table of Contents

GC-MS systems combine the features of gas chromatography and mass spectrometry to identify different substances within a test sample. The two components, used together, allow for a finer degree of substance identification than either system when used separately. The result is a quantitative analysis of the components and the mass spectrum of each component. Our GC-MS systems are available in triple quadrupole configurations and can be configured with a variety of options to suit a range of applications. Our GC-MS systems have applications in food and product safety, forensics, clinical and toxicology testing and environmental, pharmaceutical and chemical analysis.

LC-MS systems combine the separation features of liquid chromatography with the molecular identification features of mass spectrometry to separate, identify and quantify different substances within a test sample. As a complementary technique to GC-MS, which analyzes volatile compounds, LC-MS can be used to analyze a wide range of non-volatile compounds in complex samples. Our LC-MS systems are available in a wide range of configurations to suit a user’s specific needs. Although primarily used for life science applications, our LC-MS systems also have applications in food and product safety, forensics and clinical and toxicology testing, as well as environmental, pharmaceutical and chemical analysis.

FT-IR spectrometers utilize the mid- and far-infrared regions of the electromagnetic spectrum. Our FT-IR systems are commonly used for various quality control and materials research applications.

NIR spectrometers utilize the near-infrared region of the electromagnetic spectrum. Our NIR instruments are primarily used for quality and process control applications in the pharmaceutical, food and agriculture and chemical industries. The pharmaceutical industry is the leading user of NIR instruments, and applications include quality control, research and development and process analytical technology. The food and agricultural industry is the second largest user of NIR instrumentation, with an increasing demand for food, feed and beverage quality control.

Raman spectroscopy provides information on molecular structure. The mechanism of Raman scattering is different from that of infrared absorption, in that Raman and IR spectra provide complementary information. Raman is useful for the identification of both organic and inorganic compounds and functional groups. It is a nondestructive technique and can be used for the analysis of both liquids and solids. Raman is well suited for use in the polymer and pharmaceutical industries, and has applications in the metals, electronics and semiconductors industries. The technique also has applications in life sciences, forensics and artwork authentication.

Additionally, the Bruker Detection product line offers a wide range of portable analytical and bioanalytical detection systems and related products for CBRNE detection. Our customers use these devices for nuclear, biological agent and chemical agent defense applications, anti-terrorism, law enforcement and process and facilities monitoring. Our CBRNE detection products use many of the same technology platforms as our life science products, as well as additional technologies, including infrared stand-off detection and ion mobility spectrometry, for handheld chemical detectors. We also provide integrated, comprehensive detection suites that include our multiple detection systems, consumables, training and simulators.

BSI NANO Segment

The BSI Nano Segment comprises the Bruker AXS, Bruker Nano Analytics, Bruker Nano Surfaces and Metrology, Fluorescence Microscopy and Canopy Divisions. The Bruker AXS Division designs, manufactures and distributes advanced X-ray instruments that use electromagnetic radiation with extremely short wavelengths to determine the characteristics of matter and the three-dimensional structure of molecules. This includes a product portfolio of instruments based on X-ray fluorescence spectroscopy (XRF), X-ray diffraction (XRD) and X-ray micro computed tomography (µCT), or X-ray microscopy, as well as spark optical emission spectroscopy systems (S-OES) used to analyze the concentration of elements in metallic samples.

8

Table of Contents

The Bruker Nano Analytics Division manufactures and markets analytical tools for electron microscopes, including energy-dispersive X-ray spectrometers (EDS), electron backscatter diffraction systems (EBSD) and µCT accessories, as well as mobile and bench top micro X-ray fluorescence (µXRF), total reflection X-ray fluorescence spectrometers (TXRF) and handheld, portable and mobile X-ray fluorescence (HMP-XRF) spectrometry instruments.

The Bruker Nano Surfaces and Metrology Division’s products include atomic force microscopy instrumentation (AFM). Such instruments provide atomic or near atomic resolution of surface topography and nanoscale, mechanical, electrical and chemical information using nano scale probes. The Bruker Nano Surfaces and Metrology Division also provides non-contact nanometer resolution solution topography through white light interferometry and stylus profilometry. In addition, the division manufacturers and markets automated X-ray metrology, automated AFM defect-detection and photomask repair and cleaning equipment for semiconductor process control.

The Fluorescence Microscopy Division provides advanced optical fluorescence microscopy instruments with multi-photon, multipoint scanning confocal 3D super-resolution, light-sheet modalities for studies in life science applications.

The Canopy Division provides products and services to support the multi-omics needs of researchers in translational research, drug and biomarker discovery.

Customers of our BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials analysis.

During 2020, we launched several new products for the life science research market, including Vutura VXL, S2 PUMA II and Contour SP. We acquired Canopy Biosciences LLC, a manufacturer of high multiplex biomarker imaging tools for immunology, immune-oncology, cell therapy and targeted proteomics research.

The BSI NANO Segment systems are based on the following technology platforms:

XRD—Polycrystalline X-ray diffraction, often referred to as X-ray diffraction;
XRF—X-ray fluorescence, also called X-ray spectrometry, including handheld XRF systems;
SC-XRD—Single crystal X-ray diffraction, often referred to as X-ray crystallography;
µCT—X-ray micro computed tomography, X-ray microscopy;
EDS—Energy dispersive X-ray spectroscopy on electron microscopes;
EBSD—Electron backscatter diffraction on electron microscopes;
S-OES—Spark optical emission spectroscopy;
CS/ONH—Combustion analysis for carbon, sulfur, oxygen, nitrogen, and hydrogen in solids;
AFM—Atomic force microscopy;
FM—Fluorescence microscopy;
SOM—Stylus and optical metrology;
TMT—Tribology and mechanical test systems for analysis of friction and wear;
NanoIR—Nanoscale infrared spectroscopy;
Alicona—Focus variation optical technology for non-contact dimensional metrology; and
Canopy – Multiplexed fluorescence-based single cell imaging for suspended cells and tissues as well as multi-omics sample characterization.

9

Table of Contents

XRD systems investigate polycrystalline samples or thin films with single wavelength X-rays. The atoms in the polycrystalline sample scatter the X-rays to create a unique diffraction pattern recorded by a detector. Computer software processes the pattern and produces a variety of information, including stress, texture, qualitative and quantitative phase composition, crystallite size, percent crystallinity and layer thickness, composition, defects and density of thin films and semiconductor material. Our XRD systems contribute to a reduction in the development cycles for new products in the catalyst, polymer, electronic, optical material and semiconductor industries. Customers also use our XRD systems in academic and government research, as well as in a variety of other fields, including forensics, art and archaeology.

XRF systems determine the elemental composition of a material and provide a full qualitative and quantitative analysis. Our XRF systems direct X-rays at a sample, and the atoms in the sample absorb the X-ray energy. The elements in the sample then emit X-rays that are characteristic for each element. The system collects the X-rays, and the software analyzes the resulting data to determine the elements that are present. Our XRF products provide automated solutions on a turn-key basis for industrial users that require automated, controlled production processes that reduce product and process cost, increase output and improve product quality. Our XRF products cover substantially all of the periodic table and can analyze solid, powder or liquid samples.

SC-XRD systems determine the three-dimensional structures of molecules in a chemical, mineral, or biological substance being analyzed. SC-XRD systems have the capability to determine structure in both small chemical molecules and larger biomolecules. SC-XRD systems direct an X-ray beam at a solid, single crystal sample. The atoms in the crystal sample scatter the X-rays to create a precise diffraction pattern recorded by an electronic detector. Software then reconstructs a model of the structure and provides the unique arrangement of the atoms in the sample. This information on the exact arrangement of atoms in the sample is a critical part of molecular analysis and can provide insight into a variety of areas, including how a protein functions or interacts with a second molecule. Our SC-XRD systems are designed for use in the life sciences industry, academic research and a variety of other applications.

µCT is X-ray imaging in 3D, by the same method used in hospital CT scans, but on a small scale with massively increased resolution. 3D microscopy allows users to image the internal structure of objects non-destructively on a very fine scale. Bruker µCT is available in a range of easy-to-use desktop instruments, which generate 3D images of the sample’s morphology and internal microstructure with resolution down to the sub-micron level. Our µCT systems are used for numerous applications in materials research and in the life sciences industry.

EDS systems analyze the chemical composition of materials under investigation in electron microscopes by utilizing the fact that atoms of different chemical elements, when exposed to the high energy electron beam generated by the microscope, irradiate X-rays of different characteristic energy. The evaluation of the energy spectrum collected by our spectrometer allows the determination of the qualitative and quantitative chemical sample composition at the current beam position. EDS systems allow for simultaneous analysis of all elements in the periodic table, beginning with atomic number 4 (beryllium). Our EDS systems are used for a range of applications, including nanotechnology and advanced materials research, as well as materials analysis and quality control. Customers for EDS systems include industrial customers, academia and government research facilities.

EBSD systems are used to perform quantitative microstructure analysis of crystalline samples in electron microscopes. The microscope’s electron beam strikes the tilted sample and diffracted electrons form a pattern on a fluorescent screen. This pattern is characteristic of the crystal structure and orientation of the sample region from which it was generated. It provides the absolute crystal orientation with sub-micron resolution. EBSD can be used to characterize materials with regard to crystal orientation, texture, stress, strain and grain size. EBSD also allows the identification of crystalline phases and their distribution and is applied to many industries such as metals processing, aerospace, automotive, microelectronics and earth sciences.

10

Table of Contents

S-OES instruments are used for analyzing metals. S-OES covers a broad range of applications for metals analysis from pure metals trace analysis to high alloyed grades and allows for analysis of a complete range of relevant elements simultaneously. S-OES instruments pass an electric spark onto a sample, which burns the surface of the sample and causes atoms to jump to a higher orbit. Our detectors quantify the light emitted by these atoms and help our customers to determine the elemental composition of the material. This technique is widely used in production control laboratories of foundries and steel mills.

CS/ONH carrier gas systems incorporate a furnace and infrared or thermal conductivity detection to analyze inorganic materials for the determination of carbon, sulfur, nitrogen, oxygen and hydrogen. Combustion and inert gas fusion analyzers are used for applications in metal production and processing, chemicals, ceramics and cement, coal processing, oil refining and semiconductors.

AFM systems provide atomic or near-atomic resolution of material surface topography using a nano-scale probe that is brought into light contact with the sample being investigated. In addition to presenting a surface image, AFM can also provide quantitative nano-scale measurements of feature sizes, material properties, electrical information, chemical properties and other sample characteristics. Our AFM systems are used for applications in academic and governmental materials and biological research and semiconductor, data storage hard drive, LED, battery, solar cells, polymers, and pharmaceutical product development and manufacturing.

FM products use fluorescence microscopy to determine the structure and composition of life science samples. Our products include two-photon microscopes, multipoint scanning confocal microscopes, super-resolution microscopes, light-sheet microscopes, laser illumination sources, photoactivation, photostimulation and photoablation accessories and synchronization and analysis software. Two-photon microscopes allow imaging deep into tissues and cells and are used widely in neuroscience. Multipoint scanning confocal systems allow live cell imaging with rapid acquisition of images for structural and composition analysis. Super-resolution and single-molecule localization microscopy products allow imaging below the optical diffraction limit by an order of magnitude. Light-sheet based products allow fast 3D volume imaging with very low phototoxicity and photo-damage effects enabling live cell and large volume imaging.

SOM systems provide atomic or near-atomic two dimensional and three-dimensional surface resolution using white light interferometry, confocal optical and stylus profilometry methods. SOM profilers range from low-cost manual tools for single measurements to advanced, highly automated systems for production line quality assurance and quality control applications where the combination of throughput, repeatability and reproducibility is essential. SOM profilers support a range of applications in research, product development, tribology, quality control and failure analysis related to materials and machining in the automotive, orthopedic, ophthalmic, high brightness LED, semiconductor, data storage, optics and other markets.

TMT systems provide a platform for all types of common mechanical, friction, durability, scratch and indentation tests for a wide spectrum of materials. Tribology systems are utilized for both academic research of the fundamental material properties and industrial applications in the semiconductor, aerospace, petroleum, automotive and other industries.

NanoIR systems perform infrared (IR) spectroscopy at the nanoscale. Our systems use nanoprobe technology similar to what is used in our atomic force microscopes to deliver quantitative chemical information from the nanoscale to the sub-micron and macro scales. The NanoIR measurement gives the user varying physical and chemical properties with nanoscale spatial resolution in a diverse range of fields, including polymers, 2D materials, materials science, life science and the micro-electronics industry. Our systems allow nanoscale IR absorption spectroscopy with interpretable IR spectra that directly correlates to FTIR as well as the complementary technique of nanoscale s-SNOM. With our broadband sources, these systems allow broadband scientific spectroscopy.

11

Table of Contents

Alicona systems combine the functionalities of a micro coordinate measurement machine (CMM) with those of a surface measurement system. These dimensional metrology systems are based on the pioneering development of optical Focus-Variation measurement algorithms and provide the noncontact measurement of form and roughness of complex, miniaturized geometries. These systems serve many quality assurance application areas requiring precision measurement and dimensional metrology, including aerospace, automotive, precision medical products, additive manufacturing, and micro precision manufacturing.

Canopy provides digital spatial profiling services and instruments which include both our ChipCytometry profiling instrument and ChipCytometry (single cell and spatial targeted proteomics) and other services. These technologies, along with Canopy's more basic IHC and FISH services, allow researchers to elucidate gene and protein expression in a spatial context, which is useful for deep biological insight into gene expression and for the development of biomarkers. Canopy also provides transcriptional profiling services covering a variety of assays, including RNASeq and qPCR. Our multi-omic services provide data elucidating gene expression, signaling pathways, and differential expression trends on customer provided biological samples. These services generally incorporate a data analysis service as well and can be utilized with multiple types of samples from very early discovery research through clinical trials.

BEST Segment

The BEST Segment designs, manufactures and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications. Additionally, BEST develops, manufactures and markets sophisticated devices and complex tools based primarily on metallic low temperature superconductors that have applications in “big science” research, including radio frequency accelerator cavities and modules, power couplers and linear accelerators. BEST also manufactures and sells non-superconducting high technology tools, such as synchrotron and beamline instrumentation, principally to customers engaged in materials research and “big science” research projects.

Sales and Marketing

We maintain direct sales forces throughout North America, Europe, Russia, China, Japan, and elsewhere in the Asia Pacific region. We also utilize indirect sales channels to reach customers. We have various international distributors, independent sales representatives and various other representatives in parts of Asia, Latin America, Africa, the Middle East and Eastern Europe. These entities augment our direct sales force and provide coverage in areas where we do not have direct sales personnel. In addition, we have adopted a distribution business model in which we engage in strategic distribution alliances with other companies to address certain market segments. The sales cycle for our products is dependent on the size and complexity of the system and budgeting cycles of our customers. Our sales cycle is typically three to twenty-four months for academic and high-end research products and two weeks to six months for industrial products. The sales cycle of our low temperature superconducting materials is typically four to twelve months, with cycles of certain high-end materials exceeding one year. Sales of our high-end NMR and superconducting devices typically take more than one year and certain large, complex contracts can take more than two years to complete.

We have well-equipped applications and demonstration facilities and qualified application personnel who assist customers and provide product demonstrations in specific application areas. We maintain our primary demonstration facilities at our production facilities, as well as in other key market locations.

Seasonal Nature of Business

Historically, we have higher levels of revenue in the fourth quarter and lower levels of revenues in the first quarter of the year, which we believe is influenced by our customers’ budgeting cycles.

12

Table of Contents

Major Customers

We have a broad and diversified customer base and we do not depend on any single customer. No single customer accounted for more than 10% of revenue in any of the last three fiscal years or more than 10% of accounts receivable as of December 31, 2020 or 2019.

Competition

Our existing products and solutions and any products and solutions that we develop in the future may compete in multiple, highly competitive markets. In addition, there has been a trend towards consolidation in our industries and many of our competitors have substantially greater financial, technical and marketing resources than we do. Our competitors may succeed in developing and offering products that could render our products or those of our strategic partners obsolete or noncompetitive. Our competitors may also have cost and price advantages based upon the value of their currencies compared with the U.S. Dollar or Euro. In addition, many of these competitors have significantly more experience in the life sciences, chemical and materials markets. Our ability to compete successfully will depend on our ability to develop proprietary products that reach our target markets in a timely manner and are technologically superior to and/or less expensive, or more cost effective, than products marketed by our competitors. Current competitors or other companies may possess or develop technologies and products that are more effective than ours. Our technologies and products may be rendered obsolete or uneconomical by technological advances or by entirely different approaches developed by one or more of our competitors.

We also compete with companies that provide analytical or automation tools based on technologies other than those we offer. These technologies may prove to be more successful in meeting demands in the markets that our products and solutions are intended to serve. In addition, other companies may choose to enter our fields in the future. We believe that the principal competitive factors in our markets are technology-based applications expertise, product specifications, functionality, reliability, marketing expertise, distribution capability, proprietary patent portfolios and cost effectiveness.

BSI Life Science Segment Competition

The Bruker BioSpin Group competes with companies that offer magnetic resonance spectrometers, mainly JEOL and Oxford Instruments. In the field of preclinical imaging, Bruker BioSpin competes with Perkin Elmer, Mediso, Trifoil, MR Solutions and others. The Bruker CALID Group competes with a variety of companies that offer mass spectrometry-based systems. Bruker CALID’s competitors in the life science markets and chemical and applied markets include Danaher, Agilent, GE-Healthcare, Waters, Thermo Fisher Scientific, Shimadzu, Hitachi and JEOL. In the microbiology market, Bruker CALID competes with Biomerieux. In molecular diagnostics, Bruker CALID competes with a number of companies offering products for infectious disease diagnostics. Bruker CALID also competes with a variety of companies that offer molecular spectrometry-based systems, including Thermo Fisher Scientific, PerkinElmer, Agilent, Foss, ABB Bomem, Buchi, Shimadzu and Jasco. Bruker CALID’s CBRNE detection customers are highly fragmented, and it competes with a number of companies in this area, of which the most significant competitor is Smiths Detection.

BSI NANO Segment Competition

The BSI NANO Segment competes with companies that offer analytical X-ray solutions, OES systems, AFM and SOM systems and optical fluorescence systems, primarily Rigaku, Oxford Instruments, Agilent, Thermo Fisher Scientific, Ametek’s Spectro and Edax divisions, PANalytical, Park Systems, Olympus, Nikon, Zeiss and Danaher’s Leica business.

13

Table of Contents

BEST Segment Competition

BEST competes with Luvata, Western Superconducting Technologies Co., Ltd. (WST), and Jastec Co., Ltd. in low temperature superconducting materials. BEST further competes with Zanon, Mitsubishi Electric and AES in the development and supply of accelerator cavities, with Thales, Toshiba and CPI International in the development and supply of radio frequency couplers, with Mitsubishi Heavy Industries in the development and supply of superconducting accelerator modules and with AES and Thales for electron linear accelerators.

Manufacturing and Supplies

Several of our manufacturing facilities are certified under ISO 9001:2008 and ISO 13485, international quality standards. We manufacture and test our magnetic resonance products at our facilities in Faellanden, Switzerland; Wissembourg, France; and Karlsruhe, Germany. We manufacture and test our preclinical imaging products at our facilities in Ettlingen, Germany; Wissembourg, France; Kontich, Belgium; and Faellanden, Switzerland. We manufacture and test our mass spectrometry products, including CBRNE detection products, at our facilities in Bremen, Germany. We principally manufacture and test our molecular spectroscopy products, including CBRNE detection products, at our facilities in Ettlingen, Germany. We manufacture and test our X-ray, OES and AFM products at our facilities in Penang, Malaysia; Karlsruhe, Germany; Berlin, Germany; Santa Barbara, California, U.S.A.; Kennewick, Washington, U.S.A.; and Migdal Ha’Emek, Israel. We manufacture and test the majority of our energy and superconducting products at our facilities in Hanau, Germany; Bergisch Gladbach, Germany; Perth, Scotland; and Carteret, New Jersey, U.S.A. Manufacturing processes at our facilities in Europe, Israel and California, U.S.A. include all phases of manufacturing, such as machining, fabrication, subassembly, system assembly, and final testing. Our other facilities primarily perform high-level assembly, system integration and final testing. We typically manufacture critical components in-house to ensure key competence and outsource to third party manufacturers non-critical components.

We purchase materials and components from various suppliers that are either standard products or built to our specifications. We obtain some of the components included in our products from a limited group of suppliers or from a single-source supplier for items such as charge coupled device area detectors, X-ray tubes, robotics, infrared optics and others. BEST has an ongoing collaboration and a joint technology development agreement with Allegheny Technologies Incorporated to advance state-of-the-art niobium-based superconductors, including those used in MRI magnets for the medical industry, and preclinical MRI magnets used in the life-science tools industry.

Research and Development

We commit substantial capital and resources to internal and collaborative research and development projects in order to provide innovative products and solutions to our customers. We conduct research primarily to enhance system performance and improve the reliability of existing products, and to develop revolutionary new products and solutions. Our research and development efforts are conducted for the relevant products within each of the operating segments, as well as in collaboration with others on areas such as microfluidics, automation and workflow management software. We have been the recipient of government grants from Germany and the United States for various projects related to early-stage research and development. We have generally retained, at a minimum, non-exclusive rights to any items or enhancements we develop under these grants. The German government requires that we use and market technology developed under grants in order to retain our rights to the technology. We have also accepted some sponsored research contracts from private sources.

14

Table of Contents

BSI Life Science Segment Research and Development

The research and development performed in the Bruker BioSpin Group and in the CALID Group is primarily conducted at our facilities in Bremen and Ettlingen, Germany; Faellanden, Switzerland and Wissembourg, France. The Bruker BioSpin Group maintains technical competencies in core magnetic resonance technologies and single- and multimodal imaging technologies and capabilities, including NMR, EPR, MRI, MPI, PET and CT. The most recent technological innovations included Bruker’s GHz-class ultra-high field NMR product line, enabling novel research in functional structural biology of proteins and protein complexes. In 2020, we delivered and successfully installed our first NMR systems at the 1.2 GHz magnetic strength, the AvanceTM NEO 1.2 GHz NMR. In addition to ultra-high field NMR, we are also developing preclinical MRI magnets of up to 18 Tesla. We have developed and introduced various new NMR probes, including low temperature magic angle spinning (MAS) probes for the analysis of complex biomolecules and materials, as well as new CP/MAS CryoProbes for material science research. Bruker is incorporating artificial intelligence Deep Learning capabilities into its NMR software to improve signal detection and we are adding advanced software tools for automated workflows and 3D conformational and configurational analysis. We have incorporated remote monitoring tools of labs and systems to increase system protection and support our customers with expert supervision. We recently introduced our next-generation, high-performance 80 MHz FT-NMR benchtop spectrometer with new capabilities for organic and medicinal chemistry research, teaching and synthesis verification.

The Bruker CALID Group maintains technical competencies in core mass spectrometry technologies and capabilities, including: MALDI, ESI and EI/CI ion source, TOF, TOF/TOF, ion traps, MRMS, quadrupole and IMS analyzers and bioinformatics. Recent projects include the innovative timsTOF mass spectrometer for separation and analysis of unresolved compounds and conformations. The Bruker CALID Group also maintains technical competencies in core vibrational spectroscopy technologies and capabilities, including FT-IR, NIR and Raman.

BSI NANO Segment Research and Development

The research and development performed in the BSI NANO Segment is primarily conducted at our facilities in Karlsruhe, Berlin and Leipzig, Germany; Penang, Malaysia; Madison, Wisconsin, Eden Prairie, Minnesota, San Jose and Santa Barbara, California, and St. Louis, Missouri, U.S.A. The BSI NANO Segment maintains technical competencies in core X-ray technologies and capabilities, including detectors used to sense X-ray and X-ray diffraction patterns, X-ray sources and optics that generate and focus the X-rays, robotics and sample handling equipment that holds and manipulates the experimental material, and software that generates the structural data. Recent projects include fluorescence microscopy with simultaneous, all-optical stimulation and imaging platforms for optogenetics neuroscience research and light sheet cell microscopy systems, which enable brain research and high-resolution live cell research. The BSI NANO Segment also has competencies in AFM technology, which involve sub-angstrom level position and motion control, as well as sub-pico newton force control. The BSI NANO Segment technologies also include 3D optical inference-based microscopy, stylus profilometry, tribology testing, nano-indentation, optical fluorescence two-photon microscopy, multipoint scanning microscopy, high-speed, 3D super-resolution florescence microscopy and spatial biology and single-cell targeted proteomics technologies. Recent innovations include elemental analyzer systems for advanced applications and research and simultaneous, all-optical stimulation and imaging platforms for neuroscience applications.

BEST Segment Research and Development

The research and development performed in the BEST Segment is primarily conducted at our facilities in Hanau and Bergisch Gladbach, Germany; and Carteret, New Jersey, U.S.A. BEST maintains technical competencies in the production and development of low and high temperature superconducting materials and devices. BEST and CERN (European Organization for Nuclear Research, Geneva, Switzerland) have an ongoing research and development agreement to advance the state of art with niobium-tin based superconductors used in particle accelerators and other large scale scientific magnets systems.

15

Table of Contents

Intellectual Property

Our intellectual property consists of patents, copyrights, trade secrets, know-how, and trademarks. Protection of our intellectual property is a strategic priority for our businesses because of the length of time and expense associated with bringing new products through the development process and to the marketplace. We have a substantial patent portfolio, and we intend to file additional patent applications as appropriate. We believe our owned and licensed patent portfolio provides us with a competitive advantage. This portfolio permits us to maintain access to a number of key technologies. We license our owned patent rights where appropriate. We intend to enforce our patent rights against infringers, if necessary. The patent positions of life sciences tools companies involve complex legal and factual questions. As a result, we cannot predict the enforceability of our patents with certainty. In addition, we are aware of the existence from time to time of patents in certain countries, which, if valid, could impair our ability to manufacture and sell products in these countries.

We also rely upon trade secrets, know-how, trademarks, copyright protection and licensing to develop and maintain our competitive position. We generally require the execution of confidentiality agreements by our employees, consultants, and other scientific advisors. These agreements provide that all confidential information made known during the course of a relationship with us will be held in confidence and used only for our benefit. In addition, these agreements provide that we own all inventions generated during the course of the relationship.

Government Contracts

We are a party to various government contracts. Under some of these government contracts, the government may receive license or similar rights to intellectual property developed under the contract. However, under government contracts we enter we generally receive at least non-exclusive rights to any items or technologies we develop. Although we transact business with various government agencies, we believe that no government contract is of such magnitude that a renegotiation of profits or termination of the contract or subcontracts at the election of the government would have a material adverse effect on our financial results.

Government Regulation

We are required to comply with federal, state, and local environmental protection regulations. We do not expect this compliance to have a significant impact on our capital spending, earnings or competitive position.

Our products are subject to the U.S. Food and Drug Administration’s, or the FDA’s, requirements for electronic radiation emitting products, which include requirements related to record-keeping and reporting; labeling; notification; product repairs, replacements and refunds; importations; and performance standards. For example, prior to introducing a product in the United States, our Bruker AXS subsidiary provides notice to the FDA in the form of a Radiation Safety Initial Product Abbreviated Report, which provides identification information and operating characteristics of the product. If the FDA finds that the report is complete, it provides approval in the form of what is known as an accession number. Bruker AXS may not market a product until it has received an accession number. In addition, Bruker AXS submits an annual report to the FDA that includes the radiation safety history of all products it sells in the United States. Bruker AXS is required to report to the FDA incidents of accidental exposure to radiation arising from the manufacture, testing, or use of any of its products. Bruker AXS also reports installations of its products to state government regulatory agencies responsible for the regulation of radiation emitting devices. For sales in Germany, Bruker AXS registers each system with the local authorities. In some countries where Bruker AXS sells systems, Bruker AXS uses the license we obtained from the federal authorities in Germany to assist it in obtaining a license from the country in which the sale occurs.

Our Bruker AXS subsidiary possesses low-level radiation materials licenses from the local radiation safety authority, Gewerbeaufsichtsamt Karlsruhe, for its facility in Karlsruhe, Germany; and from the local radiation safety authority, Kanagawa Prefecture, for its facility in Yokohama, Japan, as well as from various other countries in which it sells its products. Our Bruker Daltonics subsidiary possesses low-level radiation licenses for facilities in Billerica, Massachusetts and Leipzig, Germany. The U.S. Nuclear Regulatory Commission also has regulations concerning the exposure of our employees to radiation.

16

Table of Contents

Certain of our clinical products are subject to regulation as medical devices in the United States by the FDA and by similar regulatory bodies in other countries where such products are sold. The regulatory requirements imposed by the FDA and other regulatory bodies govern a wide variety of product-related activities, from quality management, design and development to labeling, manufacturing, promotion, sales, and distribution. As such, we continually invest in our manufacturing infrastructure to gain and maintain certifications and registrations necessary for the relevant level of regulatory clearance. We also are required to maintain processes and systems for medical device product submissions. For example, our MALDI Biotyper CA system is subject to regulation by the FDA as a medical device and requires FDA premarket review and clearance via the 510(k) premarket notification process and our IVD-CE Certified MALDI BioTyper system is subject to regulation in the European Union under the provisions of Directive 98/79/EC. In addition, certain product changes, including changes to the product indications or label claims, could trigger the requirement for a new 510(k) or other FDA or foreign regulatory premarket submission. The process of obtaining marketing approval, authorization, or clearance from the FDA and comparable foreign regulatory authorities for new products, or for enhancements or modifications to existing products, could take a significant amount of time, require the expenditure of substantial financial and other resources, and require rigorous and expensive pre-clinical and clinical testing. Additionally, the FDA or comparable foreign regulatory authorities could impose limitations on the indications for use of our products. Should we pursue an FDA or comparable foreign regulatory authority clearance, authorization, or approval for a new device or device modification, we cannot be certain that we will receive required clearance, authorization, or approval on a timely basis or at all. The failure to receive clearance, authorization, or approval for significant new products or modifications to existing products on a timely basis or at all could have a material, adverse effect on our financial condition and results of operations.

Both before and after a medical device product is commercially released, we have ongoing responsibilities under FDA and foreign regulations. For example, we are required to comply with the FDA’s Quality System Regulation, which sets forth the good manufacturing requirements for medical devices. These include requirements related to design controls, production and process controls, process validation, purchasing controls, supplier oversight, complaint handling and investigation, corrective and preventative actions, and record-keeping. In addition, the FDA’s medical device reporting regulation requires us to provide information to the FDA whenever we become aware that there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, that a malfunction occurred which would be likely to cause or contribute to a death or serious injury upon recurrence. The FDA and comparable foreign regulatory authorities also regulate the promotion and marketing of medical devices and require that manufacturers only make promotional claims or statements that are consistent with the indications and labeling cleared, authorized, or approved by the FDA or other regulatory authorities. The FDA and comparable foreign regulatory authorities may take enforcement action against us, should the FDA determine we have engaged in “off-label” promotion or other violative marketing activities.

The European Union Directive will be replaced in May 2022 by the IVD Regulation (EU) 2017/746. The regime changes significantly with the new Regulation, which requires clinical evidence to demonstrate the claimed benefits and safety of the device in relation to its stated purpose, stricter classification and CE-marking requirements and ongoing post-market follow-up to ensure conformity. The Regulation requires new databases to be set up to track which devices are CE marked and to register clinical studies and post-market monitoring. In addition, tracing is enhanced by a Unique Device Identification (UDI) System and through requirements on other economic operators in the supply chain. Our products currently approved under the Directive, and not already placed on the market or put into service, must be recertified under the Regulation by May 2024.

17

Table of Contents

Backlog

Our backlog consists of firm orders under non-cancellable purchase orders received from customers. Total system backlog at December 31, 2020 and 2019 was approximately $2,006.7 million and $1,855.3 million, respectively. The increase in our backlog in 2020 when compared to 2019 is due to recovering performance in our BSI order bookings at December 31, 2020. We anticipate that approximately 67.3% of the backlog as of December 31, 2020 will be filled in 2021. We generally experience variable and fluctuating revenues in the first three quarters of the year, while our fourth quarter revenues have historically been stronger than the rest of the year. As a result, backlog on any particular date can be indicative of our short-term revenue performance but is not necessarily a reliable indicator of long-term revenue performance.

Human Capital

We are committed to enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Our employees are a critical component of that mission. We strive to attract, develop and retain top talent by offering our employees a challenging but rewarding work experience, as well as competitive compensation and benefits. Further, we are dedicated to creating a work environment that promotes integrity, respect and trust among our employees.

As of December 31, 2020 and 2019, we had approximately 7,400 and 7,230 full-time employees worldwide, respectively. Of these employees, approximately 1,180 and 1,225 were located in the United States at December 31, 2020 and 2019, respectively. Our senior leadership team is 67% male and 33% female.

The table below provides our employees by functional area.

Number of Employees

    

2020

    

2019

Production and distribution

 

3,570

 

3,505

Selling and marketing

 

1,770

 

1,740

General and administrative

 

825

 

780

Research and development

 

1,235

 

1,205

Total

 

7,400

 

7,230

We also devote resources to training and development, including educational assistance for career-enhancing academic and professional programs. Further, we invest time in identifying high-potential future leaders and working with them on individual development plans. We recognize that our success is based on the collective talents and dedication of those we employ, and we are highly invested in their success.

Additionally, we are committed to promoting diversity across our organization. We are actively working to expand the diversity of our workforce by embracing a variety of different perspectives and fostering an inclusive work environment for all of our employees. As part of our efforts, we seek to identify and recruit employees with diverse professional experiences, skills and backgrounds, as well employees from diverse gender, racial and ethnic backgrounds.

Available Information

We maintain a website at www.bruker.com. We make available on our website documents describing our corporate governance and our Code of Conduct. We are not including the information contained on our website as a part of, or incorporating it by reference into, this Annual Report on Form 10-K. We make available free of charge through our website our annual reports on Form 10-K, our proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to these reports filed with or furnished to the SEC pursuant to Sections 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. The SEC also maintains an internet site that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.

18

Table of Contents

ITEM 1A   RISK FACTORS

The following risk factors should be considered in conjunction with the other information included in this Annual Report on Form 10-K. This report may include forward-looking statements that involve risks and uncertainties. In addition to those risk factors discussed elsewhere in this report, we identify the following risk factors, which could affect our actual results and cause actual results to differ materially from those in the forward-looking statements.

Risk Factor Summary

Our business is subject to numerous risks and uncertainties, including those described in Item 1A “Risk Factors.” These risks include, but are not limited to, the following:

Our financial condition and results of operations for fiscal 2021 will be adversely affected by the ongoing COVID-19 pandemic;
Unfavorable economic or political conditions in the countries in which we operate may have an adverse impact on our business results or financial condition;
We derive a significant portion of our revenue from international sales and are subject to the operational risks of doing business in foreign countries;
If our products fail to achieve and sustain sufficient market acceptance across their broad intended range of applications, we will not generate expected revenue;
Our products compete in markets that are subject to rapid technological change, and one or more of the technologies underlying our products could be made obsolete by new technology;
If investment in life and material science research spending declines, our ability to generate revenue may suffer;
Any reduction in the capital resources or government funding of our customers could reduce our sales and impede our ability to generate revenue;
Disruptions at any of our manufacturing facilities could adversely affect our business;
In addition to the risks applicable to our life science and materials analysis products, our CBRNE detection products are subject to a number of additional risks, including lengthy product development and contract negotiation periods and certain risks inherent in long-term government contracts;
Our debt may adversely affect our cash flow and may restrict our investment opportunities or limit our activities;
If we lose our strategic partners, our marketing and sales efforts could be impaired;
We face risks related to sales through distributors and other third parties that we do not control, which could harm our business;
Our operations are dependent upon a limited number of suppliers and contract manufacturers;

19

Table of Contents

Supply shortages and increasing prices of raw materials could adversely affect the gross profit of the Bruker BioSpin Group and the BEST Segment;
If we are unable to effectively protect our intellectual property, third parties may use our technology, which would impair our ability to compete in our markets;
We may be involved in lawsuits to protect or enforce our patents that are brought by us which could be expensive and time consuming and, if determined adversely, could adversely affect our patent position;
Our manufacture and sale of products could lead to product liability claims for which we could have substantial liability;
Responding to claims relating to improper handling, storage or disposal of hazardous chemicals and radioactive and biological materials which we use could be time consuming and costly; and
We operate as an entrepreneurial, decentralized company, which presents both benefits and certain risks. In particular, significant growth in a decentralized operating model may put strain on certain business group resources and our corporate functions, which could materially and adversely affect our business, financial condition and results of operations.

Risks Related to Our Business and Industry

Our financial condition and results of operations for fiscal 2021 may continue to be adversely affected by the ongoing novel coronavirus disease- 2019, or COVID-19, pandemic.

In December 2019, a novel strain of coronavirus, now referred to as COVID-19, surfaced in Wuhan, China. In March 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The virus has spread globally. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to our business include temporary closures of many of our government and university customers and our suppliers, disruptions or restrictions on our employees’ and customers’ ability to travel, and delays in product installations or shipments to and from affected countries.

In an effort to halt the outbreak of COVID-19, a number of countries, including the United States, have implemented and continue to implement significant restrictions on travel, shelter in place or stay at home orders, business closures and occupancy limitations. Certain jurisdictions, including many within the United States, have also begun implementing policies with the goal of re-opening these markets only to return to restrictions in the face of increases in new COVID-19 cases or new strains of the virus. For example, a number of states, including California, Massachusetts and New Jersey where we have significant operations, issued shelter in place or stay-at-home orders during the first half of 2020. Although these states have begun implementing phased re-opening policies, many of our employees in these areas continue to work remotely and any re-openings may be delayed or pulled back if the virus continues to spread or if cases increase as a result of children returning to school. We have experienced decreased work efficiency and productivity as a result of the increased number of our employees working from home. In addition, with this remote working model where employees are increasingly accessing our systems through VPN or remote internet connections, we may be subject to increased security risks, including the risks of cyberattacks or data breaches. Additionally, if any of our key leaders contract the virus and are unable to perform their duties for a period of time as the result of illness, our business, results of operations or financial condition could be adversely affected.

In addition, in 2020, a number of our production facilities had to either temporarily close or operate on a reduced capacity. Most commercial activities in sales and marketing, and customer demonstrations and

20

Table of Contents

applications training, are either being conducted remotely or postponed. Customer purchasing departments are operating at reduced capacity, and many customers have delayed or cut capital expenditures and operating budgets. Even where customers have re-opened their sites, they may not be operating at pre-pandemic productivity levels in an effort to accommodate safety protocols. Any resurgence of the virus or the emergence of new strains of the virus may require us and our customers to close or partially close operations once again. These travel restrictions, business closures and operating reductions at Bruker, our customers, our distributors, and/or our suppliers have adversely impacted and will likely continue to adversely impact our operations worldwide, including our ability to manufacture, sell or distribute our products, as well as cause temporary closures of our foreign distributors, or the facilities of suppliers or customers. These disruptions of our employees, distributors, suppliers or customers have impacted and will likely continue to impact our global sales and operating results. During 2020, our revenue declined 4.1% compared to 2019, primarily due to COVID-19 related disruptions.

We continue to monitor and assess the effects of the COVID-19 pandemic on our commercial operations, including its continued impact on our revenue and operations in 2021 and beyond. However, we cannot at this time accurately predict what effects these conditions will ultimately have on our operations due to continued uncertainties relating to the length or the severity of the disease, the duration of the outbreak, and the length or severity of the travel restrictions, business closures, and other safety and precautionary measures imposed by the governments of impacted countries or the effectiveness of any COVID-19 vaccines.

Unfavorable economic or political conditions in the countries in which we operate may have an adverse impact on our business results or financial condition.

Our businesses and results of operations are affected by international, national and regional economic and political conditions. Our businesses or financial results may be adversely impacted by unfavorable changes in economic or political conditions in the countries and markets in which we operate, including, among others, adverse changes in interest rates or tax rates, volatility in financial and commodity markets, contraction in the availability of credit in the marketplace, and changes in capital spending patterns.

Our revenue from U.S. operations represented approximately 23% and 26% of total consolidated revenue for fiscal 2020 and 2019, respectively. Our revenue from operations in Europe represented approximately 38% and 35% of total consolidated revenue for the fiscal years 2020 and 2019, respectively. Our revenue from operations in the Asia Pacific region represented approximately 32% and 31% of total consolidated revenue in each of the corresponding periods. Economic factors that could adversely influence demand for our products include continued uncertainty about global economic conditions, including as a result of the pandemic, leading to ongoing reductions in investment, changes in government spending levels and/or priorities, the size and availability of government budgets, customers’ and suppliers’ access to credit and other macroeconomic factors affecting government, academic or industrial spending behavior. Slower economic growth or a deterioration in economic conditions could result in a decrease in government funding for scientific research, a delay in orders from current or potential customers or a reduction in purchases of our products.

We cannot predict how changes in economic conditions or political instability will affect our customers and suppliers or how any negative impact on our customers and suppliers might adversely impact our business results or financial condition.

We derive a significant portion of our revenue from international sales and are subject to the operational risks of doing business in foreign countries.

International sales account, and are expected to continue to account, for a significant portion of our total revenues. Our revenue from non-U.S. operations represented approximately 77% and 74% of our total consolidated revenue for fiscal 2020 and 2019, respectively. Our international operations are, and will continue to be, subject to a variety of risks associated with conducting business internationally, many of which are beyond

21

Table of Contents

our control. These risks, which may adversely affect our ability to achieve and maintain profitability and our ability to sell our products internationally, include:

changes in foreign currency translation rates;
changes in regulatory requirements;
legislation and regulation, including tariffs, relating to the import or export of high technology products;
the imposition of government controls;
political and economic instability, including the impact of COVID-19, the possibility of an economic recession in certain key markets such as Germany, international hostilities, acts of terrorism and governmental restrictions, inflation, trade relationships and military and political alliances;
costs and risks of deploying systems in foreign countries;
compliance with export laws and controls and trade embargoes in multiple jurisdictions;
limited intellectual property rights;
the burden of complying with a wide variety of complex foreign laws and treaties, including unfavorable labor regulations, specifically those applicable to our European operations; and
compliance with U.S. and local laws affecting the activities of U.S. companies abroad, including the United States Foreign Corrupt Practices Act, or FCPA, and local anti-bribery laws.

The United States has implemented tariffs on certain imported goods. These additional tariffs could include items imported by us from China or other countries. In addition, China has imposed tariffs on a wide range of American products in retaliation for these new American tariffs. As a result, there is a concern that the imposition of additional tariffs by the United States, could result in the adoption of additional tariffs by China and other countries as well. Any resulting trade war could negatively impact the global market for scientific instruments and could have a significant adverse effect on our business. The imposition of tariffs on items imported by us from China or other countries could increase our costs and could result in lowering our gross margin on products sold. Conversely, China imposing tariffs on items that we export to China, could adversely impact our customers’ ability to purchase our products and our competitive position in China or increase our costs, which could have a material adverse effect on our business and results of operations.

We must also comply with the European Union General Data Protection Regulation (GDPR) and other similar regulations in other countries. The goal of the regulation is to increase individual rights and protections for personal data located in or originating from the European Union. GDPR is extraterritorial in that it applies to all business within the European Union and any business located outside of the European Union that processes personal data of individuals located within the European Union. There are significant fines associated with non-compliance. In 2020, the Court of Justice of the European Union invalidated the EU-US Privacy Shield Framework, removed a key mechanism for transfers of personal data from the European Union to the United States and altered the international data transfer under GDPR. The decision has caused uncertainty for multinational companies about how they can properly transfer personal data from the EU to the US and the cost and effort to comply with such decision could cause disruption of data transfers and have a material adverse effect on our business.

While the impact of these factors is difficult to predict, any one or more of these factors could adversely affect our operations in the future.

22

Table of Contents

We previously had identified material weaknesses in our internal control over financial reporting, which has now been remediated. Any failure to maintain effective internal control over financial reporting could result in material misstatements in our financial statements and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our securities to decline.

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, management identified material weaknesses in our internal control over financial reporting as of the end of the end of that fiscal year.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Effective internal controls are necessary for us to provide reliable and accurate financial statements and to effectively prevent fraud. We devote significant resources and time to comply with the internal control over financial reporting requirements of the Sarbanes Oxley Act of 2002 and continue to enhance our controls. In the year ended December 31, 2020, we remediated the previously disclosed material weakness in our internal controls over the accounting for income taxes and revenue recognition. However, we cannot be certain that we will be able to prevent future significant deficiencies or material weaknesses. Inadequate internal controls could cause investors to lose confidence in our reported financial information, which could have a negative effect on investor confidence in our financial statements, the trading price of our stock and our access to capital.

We may lose money when we exchange foreign currency received from international sales into U.S. Dollars.

A significant portion of our business is conducted in currencies other than the U.S. Dollar, which is our reporting currency. As a result, currency fluctuations among the U.S. Dollar and the currencies in which we do business have caused, and will continue to cause, foreign currency translation gains and losses. In addition, currency fluctuations could cause the price of our products to be more or less competitive than our principal competitors’ products. Currency fluctuations will increase or decrease our cost structure relative to those of our competitors, which could lessen the demand for our products and affect our competitive position. From time to time we enter into certain hedging transactions and/or option and foreign currency exchange contracts which are intended to offset some of the market risk associated with our sales denominated in foreign currencies. We cannot predict the effectiveness of these transactions or their impact upon our future operating results, and from time to time they may negatively affect our quarterly earnings.

Our reported financial results may be adversely affected by fluctuations in currency exchange rates.

In addition to the foreign currency exposure associated with differences between where our products are manufactured and sold by us and our competitors, our exposure to currency exchange rate fluctuations results from the currency translation exposure associated with the preparation of our consolidated financial statements, as well as from the exposure associated with transactions of our subsidiaries that are denominated in a currency other than the respective subsidiary’s functional currency. While our financial results are reported in U.S. Dollars, the financial statements of many of our subsidiaries outside the U.S. are prepared using the local currency as the functional currency. During consolidation, these results are translated into U.S. Dollars by applying appropriate exchange rates. As a result, fluctuations in the exchange rate of the U.S. Dollar relative to the local currencies in which our foreign subsidiaries report could cause significant fluctuations in our reported results. Moreover, as exchange rates vary, revenue and other operating results may differ materially from our expectations. The effects of changes in currency exchange rates increased our 2020 revenue by approximately $29.4 million, or 1.4%, decreased our 2019 revenue by approximately $50.3 million, or 2.7%, and increased our 2018 revenue by approximately $25.5 million, or 1.4%. Adjustments resulting from financial statement translations are included as a separate component of shareholders’ equity. In the years ended December 31, 2020 and 2019, we recorded net gains from currency translation adjustments of $22.0 million and net losses of $20.0 million, respectively.

23

Table of Contents

Additionally, to the extent monetary assets and liabilities, including cash and debt, are held in a different currency than the reporting subsidiary’s functional currency, fluctuations in currency exchange rates may have a significant impact on our reported financial results, and may lead to increased earnings volatility. We may record significant gains or losses related to both the translation of assets and liabilities held by our subsidiaries into local currencies and the remeasurement of inter-company receivables and loan balances.

Goodwill, intangible assets and other long-lived assets are subject to impairment which could negatively impact our operating results.

We have recorded goodwill, intangible assets and other long-lived assets that must be periodically evaluated for potential impairment. We assess the realizability of the reported goodwill, intangible assets and other long-lived assets annually, as well as whenever events or changes in circumstances indicate that the assets may be impaired. These events or circumstances generally include operating losses or a significant decline in the earnings associated with the reporting unit these assets are reported within. A decline in our stock price and market capitalization may also cause us to consider whether goodwill, intangible assets and other long-lived assets may require an impairment assessment. Our ability to realize the value of these assets will depend on the future cash flows of the reporting unit in addition to how well we integrate the businesses we acquire. We did not record any impairment losses for the year ended December 31, 2020. We have recorded impairment losses of $1.7 million and $0.6 million for the years ended December 31, 2019 and 2018, respectively.

If our products fail to achieve and sustain sufficient market acceptance across their broad intended range of applications, we will not generate expected revenue.

Our business strategy depends on our ability to successfully commercialize a broad range of products based on our technology platforms, including magnetic resonance technology, pre-clinical imaging technology, mass spectrometry technology, X-ray technology, atomic force microscopy technology, stylus and optical metrology technology, fluorescence microscopy technology, infrared technology and superconducting magnet technologies for use in a variety of life science, chemistry and materials analysis applications. Some of our products have only recently been commercially launched and have achieved only limited sales to date. The commercial success of our products depends on obtaining and expanding market acceptance by a diverse array of industrial, academic, clinical, pharmaceutical, biotechnology, applied, medical research and governmental customers around the world. We may fail to achieve or sustain substantial market acceptance for our products across the full range of our intended applications or in one or more of our principal intended applications. Any such failure could decrease our sales and revenue. To succeed, we must convince substantial numbers of potential customers to invest in new systems or replace their existing techniques with techniques employing our systems. Limited funding available for capital acquisitions by our customers, as well as our customers’ own internal purchasing approval policies, could hinder market acceptance of our products. Our intended customers may be reluctant to make the substantial capital investment generally needed to acquire our products or to incur the training and other costs involved with replacing their existing systems with our products. We also may not be able to convince our intended customers that our systems are an attractive and cost-effective alternative to other technologies and systems for the acquisition, analysis and management of molecular, cellular and microscopic information. Because of these and other factors, our products may fail to gain or sustain market acceptance.

Our products compete in markets that are subject to rapid technological change, and one or more of the technologies underlying our products could be made obsolete by new technology.

The market for discovery and analysis tools is characterized by rapid technological change and frequent new product introductions. Rapidly changing technology could make some or all of our product lines obsolete unless we are able to continually improve our existing products and develop new products. Because substantially all of our products are based on our technology platforms, including magnetic resonance technology, mass spectrometry technology, X-ray technology, atomic force microscopy technology, fluorescence microscopy technology, stylus and optical metrology technology and infrared technology, we are particularly vulnerable to any technological advances that would make these techniques obsolete as the basis for analytical systems in any

24

Table of Contents

of our markets. To meet the evolving needs of our customers, we must rapidly and continually enhance our current and planned products and services and develop and introduce new products and services. In addition, our product lines are based on complex technologies that are subject to rapid change as new technologies are developed and introduced in the marketplace. We may have difficulty in keeping abreast of the rapid changes affecting each of the different markets we serve or intend to serve. If we fail to develop and introduce products in a timely manner in response to changing technology, market demands or the requirements of our customers, our product sales may decline, and we could experience significant losses.

We face substantial competition. If we fail to compete effectively, it could harm our business results and materially impact the value of our company.

We face substantial competition in our industries and we expect that competition in all of our markets will increase further. Currently, our principal competition comes from established companies providing products using existing technologies that perform many of the same functions for which we market our products. A number of our competitors have expanded their market share in recent years through business combinations. Other companies also may choose to enter our fields in the future. Our competitors may develop or market products that are more effective or commercially attractive than our current or future products or that may render our products obsolete. Competition has in the past subjected, and is likely in the future to subject, our products to pricing pressure. Many of our competitors have more experience in the market and substantially greater financial, operational, marketing and technical resources than we do, which could give them a competitive advantage in areas such as research and development, production, marketing and distribution. Our ability to compete successfully will depend, in part, on our ability to develop proprietary products that reach the market in a timely manner and are technologically superior to, less expensive than, or more cost-effective than, other currently marketed products.

If investment in life and material science research spending declines, our ability to generate revenue may suffer.

We are dependent, both directly and indirectly, upon general investment in life science research, particularly in the research and development budgets of the pharmaceutical and biotechnology industries, and in material science research as well as upon the financial condition and funding priorities of various governments and government agencies. Since our inception, both we and our academic collaborators and customers have benefited from various governmental contracts and research grants. Whether we or our academic collaborators will continue to be able to attract these grants depends not only on the quality of our products, but also on general spending patterns of public institutions.

Any reduction in the capital resources or government funding of our customers could reduce our sales and impede our ability to generate revenue.

A significant portion of our sales are capital purchases by our customers. The spending policies of our customers could have a significant effect on the demand for our products. These policies are based on a wide variety of factors, including the resources available to make purchases, the spending priorities among various types of equipment, policies regarding spending during recessionary periods and changes in the political climate.

Any changes in capital spending or changes in the capital budgets of our customers could significantly reduce demand for our products. The capital resources of our life science and other corporate customers may be limited by the availability of equity or debt financing. Any significant decline in research and development expenditures by our life science and material science customers could significantly decrease our sales. In addition, a substantial portion of our sales are to non-profit and government entities, which are dependent on government support for scientific research. Any decline in this support could decrease the ability of these customers to purchase our products.

25

Table of Contents

Disruptions at any of our manufacturing facilities could adversely affect our business.

We have manufacturing facilities located in the United States, Europe, Israel and Malaysia. Many of our products are developed and manufactured at single locations, with limited alternate facilities. If we experience any significant disruption of those facilities for any reason, such as strikes or other labor unrest, power interruptions, fire, earthquakes, or other events beyond our control, we may be unable to manufacture the relevant products at previous levels or at all. A reduction or interruption in manufacturing could harm our customer relationships, impede our ability to generate revenues from our backlog or obtain new orders and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

If employees were to engage in a strike or other work stoppage or interruption, our business, results of operations, financial condition and liquidity could be materially adversely affected.

Many of our employees are represented by workers’ councils and labor unions in certain jurisdictions, primarily in Germany and France. If disputes with these employees arise, or if our workers engage in a strike or other work stoppage or interruption, we could experience a significant disruption of, or inefficiencies in, our operations or incur higher labor costs, which could have a material adverse effect on our business, results of operations, financial condition and liquidity.

In addition to the risks applicable to our life science and materials analysis products, our CBRNE detection products are subject to a number of additional risks, including lengthy product development and contract negotiation periods and certain risks inherent in long-term government contracts.

Our CBRNE detection products are subject to many of the same risks associated with our life science products, including vulnerability to rapid technological change, dependence on mass spectrometry and other technologies and substantial competition. In addition, our CBRNE detection products and certain FT-IR products are generally sold to government agencies under long-term contracts. These contracts generally involve lengthy pre-contract negotiations and product development. We may be required to devote substantial working capital and other resources prior to obtaining product orders. As a result, we may incur substantial costs before we recognize revenue from these products. Moreover, in return for larger, longer-term contracts, our customers for these products often demand more stringent acceptance criteria. These criteria may also cause delays in our ability to recognize revenue from sales of these products. Furthermore, we may not be able to accurately predict in advance our costs to fulfill our obligations under these long-term contracts. If we fail to accurately predict our costs, due to inflation or other factors, we could incur significant losses. Also, the presence or absence of such contracts may cause substantial variation in our results of operations between fiscal periods and, as a result, our results of operations for any given fiscal period may not be predictive of our results for subsequent fiscal periods. The resulting uncertainty may have an adverse impact on our stock price.

We rely on information technology to support our operations and reporting environments. A security failure of that technology, including with respect to cybersecurity, could impact our ability to operate our businesses effectively, adversely affect our financial results, damage our reputation and expose us to potential liability or litigation.

We use information systems to carry out our operations and maintain our business records. Some systems are internally managed and some are maintained by third-party service providers. Our ability to conduct business could be materially and adversely affected if these systems or resources are compromised, damaged or fail. This could be a result of a cyber-incident, social engineering scam, hacking, phishing attempts, malware, natural disaster, hardware or software corruption, failure or error, telecommunications system failure, service provider error or failure, intentional or unintentional personnel actions or other disruption.

26

Table of Contents

In the ordinary course of business, we collect and store sensitive data, including intellectual property, other proprietary information and personally identifiable information. Despite our security measures, our information technology and infrastructure may be vulnerable to cyber-attacks by hackers or breached due to employee error, malfeasance, or other disruptions. If this data is compromised, destroyed or inappropriately disclosed, it could have a material adverse effect, including damage to our reputation, loss of customers, significant expenses to address and resolve the issues, fines or litigation or other proceedings by affected individuals, business partners or regulatory authorities.

Our debt may adversely affect our cash flow and may restrict our investment opportunities or limit our activities.

As of December 31, 2020, we had outstanding an aggregate principal amount of debt totaling approximately $846.9 million. We also had the ability to borrow an additional $599.9 million available under our existing credit facility. Most of our outstanding debt is in the United States and there are substantial cash requirements in the United States to service debt interest obligations, fund operations, capital expenditures and our declared dividends and finance potential acquisitions or share repurchases. Our ability to satisfy our debt obligations and meet our other liquidity needs depends on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our debt obligations or provide sufficient funds for our other objectives. If we are unable to service our debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures or suspend our dividend payments and share repurchases. We may not be able to obtain additional financing on terms acceptable to us or at all. Furthermore, a majority of our cash, cash equivalents and short-term investments is generated from foreign operations, with $514.9 million, or 70.4% held by foreign subsidiaries as of December 31, 2020. Our financial condition and results of operations could be adversely impacted if we are unable to maintain a sufficient level of cash flow in the United States to address our funding requirements through cash from operations and timely repatriation of cash from overseas or other sources obtained at an acceptable cost.

Additionally, the agreements governing our debt require that we maintain certain financial ratios related to maximum leverage and minimum interest coverage and contain affirmative and negative covenants, including among others, timely provision of audited financial statements, restrictions on liens, indebtedness of the Company and its subsidiaries, asset sales, dividends and transactions with affiliates. Our ability to comply with these financial restrictions and covenants is dependent on our operations and performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as foreign currency translation rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under the facility and require us to prepay the debt before its scheduled due date.

The transition away from LIBOR may adversely affect our cost to obtain financing.

On July 27, 2017, the U.K. Financial Conduct Authority announced that it intends to stop persuading or compelling banks to submit London Interbank Offered Rate, or LIBOR, rates after 2021. As a result, LIBOR may be discontinued in 2021. While there is no consensus on what rate or rates may become accepted alternatives to LIBOR, the Alternative Reference Rates Committee, a steering committee comprised of U.S. financial market participants, selected and the Federal Reserve Bank of New York started in May 2018 to publish the Secured Overnight Finance Rate, or SOFR, as an alternative to LIBOR. SOFR is a broad measure of the cost of borrowing cash in the overnight U.S. treasury repo market. At this time, it is impossible to predict whether the SOFR or another reference rate will become an accepted alternative to LIBOR. The manner and impact of this transition may materially adversely affect the trading market for LIBOR-based securities, which may result in an increase in borrowing costs under our credit agreements and term loan agreement. Any replacement for LIBOR may result in an effective increase in the applicable interest rate on our current or future debt obligations, including our credit agreements and term loan agreement.

27

Table of Contents

Changes in our effective income tax rate could adversely affect our results of operations.

We are subject to income taxes in both the United States and various foreign jurisdictions and our domestic and international tax liabilities are largely dependent upon the distribution of income among these different jurisdictions. Various factors may have favorable or unfavorable effects on our effective income tax rate. These factors include interpretations of existing tax laws, the accounting for stock options and other share-based compensation, changes in tax laws and rates, future levels of research and development spending, changes in accounting standards, changes in the mix of earnings in the various tax jurisdictions in which we operate, the outcome of examinations by the U.S. Internal Revenue Service and other tax authorities, the accuracy of our estimates for unrecognized tax benefits and realization of deferred tax assets and changes in overall levels of pre-tax earnings. A change in tax laws, treaties or regulations, or their interpretation, of any country in which we operate could result in a higher tax rate on our earnings, which could result in a significant negative impact on our earnings and cash flow from operations. In addition to the passage of the Tax Cuts and Jobs Act in 2017 in the United States, there are currently multiple initiatives for comprehensive tax reform underway in other key jurisdictions where we have operations. We assess the impact of various international tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations that could result in a material impact on our income taxes. We cannot predict whether any other specific legislation will be enacted or the terms of any such legislation. However, if such proposals were enacted, or if modifications were to be made to certain existing treaties, the consequences could have a materially adverse impact on us, including increasing our tax burden, increasing costs of our tax compliance or otherwise adversely affecting our financial condition, results of operations and cash flows.

Various international tax risks could adversely affect our earnings and cash flows.

We are subject to international tax risks. We could be subject to double taxation on income related to operations in certain countries that do not have tax treaties with the country of the trading partner. In addition, we may have a higher effective income tax rate than that of other companies in our industry if losses incurred by one operating company are not available to offset the income of an operating company located in another country. Also, distributions of earnings and other payments received from our subsidiaries may be subject to withholding taxes imposed by the countries where they are operating or are incorporated. If these foreign countries do not have income tax treaties with the United States or the countries where our subsidiaries are incorporated, we could be subject to high rates of withholding taxes on these distributions and payments. Additionally, the amount of the credit that we may claim against our U.S. federal income tax for foreign income taxes paid or accrued is subject to many limitations which may significantly restrict our ability to claim a credit for all of the foreign taxes we pay.

We currently have reserves established for potential tax liabilities. If these reserves are challenged, and we are unable to successfully defend our tax positions, a negative impact to our cash flows could result.

The unpredictability and fluctuation of our quarterly results may adversely affect the trading price of our common stock.

Our revenues and results of operations have in the past and will in the future vary from quarter to quarter due to a number of factors, many of which are outside our control and any of which may cause our stock price to fluctuate. The primary factors that may affect us include the following:

the timing of sales of our products and services;
the timing of recognizing revenue and deferred revenue under U.S. GAAP;
changes in our pricing policies or the pricing policies of our competitors;
increases in sales and marketing, product development or administration expenses;
the mix of services provided by us and third-party contractors;

28

Table of Contents

our ability to attain and maintain quality levels for our products;
costs related to acquisitions of technology or businesses; and

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

the timing of governmental stimulus programs and academic research budgets;
the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received;
foreign currency exchange rates;
the time it takes for us to receive critical materials to manufacture our products;
general economic conditions;
the time it takes to satisfy local customs requirements and other export/import requirements;
the time it takes for customers to construct or prepare their facilities for our products; and
the time required to obtain governmental licenses.

These factors have in the past affected the amount and timing of revenue recognized on sales of our products and receipt of related payments and will continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance.

Historically we have higher levels of revenue in the fourth quarter of the year compared to the first, second and third quarters, which we believe is primarily the result of our customers’ budgeting cycles. Quarter-to-quarter comparisons of our results of operations should not be relied upon as an indication of our future performance. It is likely that in some future quarters, our results of operations may be below the expectations of public market analysts and investors. In this event, the price of our common stock may fall.

The ownership of our shares is highly concentrated, which could cause or exacerbate volatility in our share price as well as have significant influence over us.

As of February 18, 2021, Laukien family members, including our Chairman, President and Chief Executive Officer Frank Laukien and his brother, Joerg Laukien, owned, in the aggregate, approximately 31% of our outstanding common stock. We may also repurchase shares in the future, which could further increase the concentration of our share ownership. Because of this reduced liquidity, the trading of relatively small quantities of shares by our shareholders could disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously if a large number of our shares were sold on the market without commensurate demand, as compared to a company with greater trading liquidity that could better absorb those sales without adverse impact on its share price. These stockholders may also exercise substantial influence over all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This could have the effect of delaying or preventing a change in control of our company and will make some transactions difficult to accomplish without the support of these stockholders.

29

Table of Contents

The loss of key personnel or an inability to attract and retain additional personnel could affect our ability to successfully grow our business.

We are highly dependent upon the continued service and performance of our CEO and other members of senior management and key finance, technical, scientific and production personnel, any of whom may cease their employment with us at any time with minimal advance notice. Because the expertise of these individuals is highly specific and takes years to develop, we face intense competition for these individuals from many other companies. The loss of one or more of our key employees may significantly delay or prevent the achievement of our business objectives, and our failure to attract and retain suitably qualified individuals or to adequately plan for succession could have an adverse effect on our ability to implement our business plan.

Dividends on our common stock could be reduced or eliminated in the future.

In recent years, we have paid dividends on our common stock. In February 2021, we announced that our Board had declared a quarterly dividend of $0.04 per share that will be payable in March 2021. There is no guarantee that such dividends will continue indefinitely. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Risks Related to Our Dependence on Third Parties

If we lose our strategic partners, our marketing and sales efforts could be impaired.

A substantial portion of our sales of selected products consists of sales to third parties who incorporate our products into their systems. These third parties are responsible for the marketing and sales of their systems. We have little or no control over their marketing and sales activities or how they use their resources. Our present or future strategic partners may or may not purchase sufficient quantities of products from us or perform appropriate marketing and sales activities. In addition, if we are unable to maintain our relationships with strategic partners, our businesses may suffer. Failures by our present or future strategic partners, or our inability to maintain existing or enter into new arrangements with strategic partners for product distribution, could materially impede the growth of our businesses and our ability to generate sufficient revenue and profits.

We face risks related to sales through distributors and other third parties that we do not control, which could harm our business.

We sell some products through third party agents, including distributors and value-added resellers. This exposes us to various risks, including competitive pressure, concentration of sales volumes, credit risks, and compliance risks. We may rely on one or a few key distributors for a product or market, and the loss of these distributors could reduce our revenue and net earnings. Distributors may also face financial difficulties, including bankruptcy, which could harm our collection of accounts receivable. Risks related to our use of distributors may reduce sales, increase expenses, and weaken our competitive position. Moreover, violations of the FCPA or similar anti-bribery laws by distributors or other third-party agents could materially and adversely impact our business, reputation and results of operations.

30

Table of Contents

Dependence on contract manufacturing may adversely affect our ability to bring products to market and damage our reputation.

As part of our efforts to streamline our operations and reduce our operating costs, we outsource certain aspects of our manufacturing processes and continue to evaluate additional outsourcing. If our contract manufacturers fail to perform their obligations in a timely manner or at satisfactory quality levels, our ability to bring products to market and our reputation could suffer. For example, during a market upturn, our contract manufacturers may be unable to meet our demand requirements, which may preclude us from fulfilling our customers’ orders on a timely basis. The ability of these manufacturers to perform is largely outside our control. Additionally, changing or replacing our contract manufacturers could cause disruptions or delays. Problems with outsourced manufacturing could result in lower revenues and unexecuted efficiencies, and adversely affect our financial condition and results of operations.

Our operations are dependent upon a limited number of suppliers and contract manufacturers.

We currently purchase components used in our products from a limited number of outside suppliers. Our reliance on a limited number of suppliers could result in time delays associated with redesigning a product due to an inability to obtain an adequate supply of required components and reduced control over pricing, quality and timely delivery. Any of these factors could adversely affect our revenues and profitability. In particular, our X-ray microanalysis business, which manufactures and sells accessories for electron microscopes, is partially dependent on cooperation from larger manufacturers of electron microscopes. Additionally, our elemental analysis business purchases certain optical detectors from a single supplier, PerkinElmer, Inc., the sole supplier of these detector components. Bruker CALID purchases detectors and power supplies from sole or limited source suppliers and its focal plane array detectors from a single supplier, Lockheed Martin Corporation. Similarly, Bruker BioSpin obtains various components from sole or limited source suppliers and BEST obtains various raw materials and uses key production equipment from sole or limited source suppliers or contract manufacturers. There are limited, if any, available alternatives to these suppliers. The existence of shortages of these components or the failure of delivery with regard to these components could have a material adverse effect upon our revenues and margins. In addition, price increases from these suppliers or contract manufacturers could have a material adverse effect upon our gross margins.

Because of the scarcity of some components, we may be unable to obtain an adequate supply of components, or we may be required to pay higher prices or to purchase components of lesser quality. Any delay or interruption in the supply of these or other components could impair our ability to manufacture and deliver our products, harm our reputation and cause a reduction in our revenues. In addition, any increase in the cost of the components that we use in our products could make our products less competitive and decrease our gross profits. We may not be able to obtain sufficient quantities of required components on the same or substantially the same terms. Additionally, consolidation among our suppliers could result in other sole source suppliers for us in the future. Other events that could affect our ability to source materials, manufacture or distribute our products include fire, natural disaster or extreme weather or a pandemic and the impact of those events on our and our suppliers’ and contract manufacturers’ operations.

Supply shortages and increasing prices of raw materials could adversely affect the gross profit of the Bruker BioSpin Group and the BEST Segment.

The last few years have seen periodic supply shortages and sharp increases in the prices for various raw materials, in part due to high demand from developing countries. Bruker BioSpin and BEST rely on some of these materials for the production of their products. In particular, for its superconducting magnet production, both for the horizontal and vertical magnet series, Bruker BioSpin relies on the availability of copper, steel and the metallic raw materials for traditional low-temperature superconducting wires. Similarly, BEST relies on the availability of niobium titanium for its production of low-temperature superconducting materials and devices. Higher prices for these commodities will increase the production cost of superconducting wires and superconducting magnets and may adversely affect gross profits.

31

Table of Contents

The prices of copper and certain other raw materials used for superconductors have increased significantly over the last decade. Since copper is a main constituent of low temperature superconductors, this may affect the price of superconducting wire. This type of increase would have an immediate effect on the production costs of superconducting magnets and may negatively affect the profit margins for those products. In addition, an increase in raw material costs could affect the production cost of the superconducting wire produced by BEST and of superconducting wire used by Bruker BioSpin.

Bruker BioSpin and its customers also rely on liquid helium to operate superconducting magnets. Helium is controlled by the Federal Helium Reserve and is subject to price changes. Shortages of liquid helium associated with federal price controls or depleted natural reserves could have an adverse impact on producing and operating BioSpin’s superconducting magnets and may also drive increases in helium pricing and negatively impact the profit margins of those products.

Risks Related to Our Intellectual Property Rights

Our success depends on our ability to operate without infringing or misappropriating the proprietary rights of others.

Our commercial success depends on avoiding the infringement of other parties’ patents and proprietary rights as well as avoiding the breach of any licenses relating to our technologies and products. Given that there may be patents of which we are unaware, particularly in the United States where patent applications are confidential, avoidance of patent infringement may be difficult. Various third parties hold patents which may relate to our technology, and we may be found in the future to infringe these or other patents or proprietary rights of third parties, either with products we are currently marketing or developing or with new products which we may develop in the future. If a third-party holding rights under a patent successfully asserts an infringement claim with respect to any of our current or future products, we may be prevented from manufacturing or marketing our infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. We may not be able to obtain such a license on commercially reasonable terms, if at all, especially if the patent holder is a competitor. In addition, even if we can obtain a license, it may be non-exclusive, which will permit others to practice the same technology licensed to us. We also may be required to pay substantial damages to the patent holder in the event of infringement. Under some circumstances in the United States these damages could include damages equal to triple the actual damages the patent holder incurs. If we have supplied infringing products to third parties for marketing by them or licensed third parties to manufacture, use or market infringing products, we may be obligated to indemnify these third parties for any damages they may be required to pay to the patent holder and for any losses the third parties may sustain themselves as the result of lost sales or license payments they are required to make to the patent holder. Any successful infringement action brought against us may also adversely affect marketing of the infringing product in other markets not covered by the infringement action, as well as our marketing of other products based on similar technology. Furthermore, we will suffer adverse consequences from a successful infringement action against us even if the action is subsequently reversed on appeal, nullified through another action or resolved by settlement with the patent holder. The damages or other remedies awarded, if any, may be significant. As a result, any successful infringement action against us may harm our business.

32

Table of Contents

If we are unable to effectively protect our intellectual property, third parties may use our technology, which would impair our ability to compete in our markets.

Our continued success will depend in significant part on our ability to obtain and maintain meaningful patent protection for our products throughout the world. We rely on patents to protect a significant part of our intellectual property and to enhance our competitive position. However, our presently pending or future patent applications may not issue as patents, and any patent previously issued to us may be challenged, invalidated, held unenforceable or circumvented. Furthermore, the claims in patents which have been issued, or which may be issued to us in the future, may not be sufficiently broad to prevent third parties from producing competing products similar to our products. In addition, the laws of various foreign countries in which we compete may not protect our intellectual property to the same extent as do the laws of the United States. Failure to obtain adequate patent protection for our proprietary technology could materially impair our ability to be commercially competitive.

In addition to patent protection, we also rely on the protection of trade secrets, know-how and confidential and proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we generally seek to enter into confidentiality agreements with our employees, consultants and strategic partners upon the commencement of a relationship with us. However, we may not obtain these agreements in all circumstances. In the event of unauthorized use or disclosure of this information, these agreements, even if obtained, may not provide meaningful protection for our trade secrets or other confidential information. In addition, adequate remedies may not exist in the event of unauthorized use or disclosure of this information. The loss or exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our operating results, financial condition and future growth prospects. Furthermore, others may have, or may in the future independently develop, substantially similar or superior know-how and technology.

We may be involved in lawsuits to protect or enforce our patents that are brought by us which could be expensive and time consuming and, if determined adversely, could adversely affect our patent position.

In order to protect or enforce our patent rights, we may initiate patent litigation against third parties, and we may be similarly sued by others. We may also become subject to interference proceedings conducted in the patent and trademark offices of various countries to determine the priority of inventions. The defense and prosecution, if necessary, of intellectual property suits, interference proceedings and related legal and administrative proceedings is costly and diverts our technical and management personnel from their normal responsibilities. We may not prevail in any of these suits. An adverse determination of any litigation or defense proceedings could put our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments in the litigation. If securities analysts or investors perceive these results to be negative, it could have a substantial negative effect on the trading price of our common stock.

On September 25, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (Zeiss), sued Luxendo GmbH (Luxendo), a subsidiary of Bruker Corporation, for infringement of a recently registered German utility model patent licensed to Zeiss pertaining to one specific Luxendo product category. We are vigorously defending against these claims.

33

Table of Contents

On September 23, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Micromass UK Limited, a subsidiary of Waters Corporation, sued Bruker Corporation, as well as its affiliate, Bruker Daltonik GmbH, for infringement of a European patent pertaining to our timsTOF product line. On February 17, 2020, Micromass expanded its complaint in Düsseldorf to assert another recently granted European patent in Germany. We are vigorously defending against these claims and we do not expect any material losses associated with this matter in excess of amounts already accrued.

Risks Related to Legal, Regulatory and Compliance

Our manufacture and sale of products could lead to product liability claims for which we could have substantial liability.

The manufacture and sale of our products expose us to product liability claims if any of our products cause injury or are found otherwise unsuitable during manufacturing, marketing, sale or customer use. In particular, if one of our CBRNE detection products malfunctions, this could lead to civilian or military casualties in a time of unrest, exposing us to increased potential for high-profile liability. If our CBRNE detection products malfunction by generating a false-positive to a potential threat, we could be exposed to liabilities associated with actions taken that otherwise would not have been required. Additionally, the nuclear magnetic resonance, research magnetic resonance imaging, Fourier transform mass spectrometry and certain electron paramagnetic resonance magnets of Bruker BioSpin utilize high magnet fields and cryogenics to operate at approximately 4 Kelvin, the temperature of liquid helium. There is an inherent risk of potential product liability due to the existence of these high magnetic fields, associated stray fields outside the magnet, and the handling of the cryogens associated with superconducting magnets. In addition, our MALDI Biotyper product has an IVD-CE mark and U.S. FDA approval and is used for the identification of microorganisms. Misidentification or a false-negative of certain viruses, bacteria, yeasts or fungi could lead to inappropriate treatment for patients and could expose us to product liability claims.

A successful product liability claim brought against us in excess of, or outside the coverage of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations. We may not be able to maintain product liability insurance on acceptable terms, if at all, and insurance may not provide adequate coverage against potential liabilities.

Responding to claims relating to improper handling, storage or disposal of hazardous chemicals and radioactive and biological materials which we use could be time consuming and costly.

We use controlled hazardous and radioactive materials in our business and generate wastes that are regulated as hazardous wastes under U.S. federal, and Massachusetts, California, New Jersey, Washington and Wisconsin state environmental and atomic energy regulatory laws and under equivalent provisions of law in those and other jurisdictions in which our research and manufacturing facilities are located. Our use of these substances and materials is subject to stringent, and periodically changing, regulation that can impose costly compliance obligations on us and has the potential to adversely affect our manufacturing activities. The risk of accidental contamination or injury from these materials cannot be completely eliminated. If an accident with these substances occurs, we could be held liable for any damages that result, in addition to incurring clean-up costs and liabilities, which can be substantial. Additionally, an accident could damage our research and manufacturing facilities resulting in delays and increased costs.

34

Table of Contents

We are subject to environmental laws and regulations, which may impose significant compliance or other costs on us.

Our manufacturing, product development and research and development operations and processes involve the controlled use of certain hazardous materials. In addition, we own and/or lease a number of facilities, some of which have been in operation for many decades, where we or others may have used substances or generated and disposed of wastes which are considered hazardous or may be considered hazardous in the future. We also have acquired various companies which historically may have used certain hazardous materials and which may have owned and/or leased facilities at which hazardous materials have been used. For all of these reasons, we are subject to federal, state, foreign, and local laws and regulations governing the use, manufacture, storage, transportation, handling, treatment, remediation, and disposal of hazardous materials and certain waste products. We have potential liability under these laws and regulations with respect to the remediation of past contamination in certain of the facilities we now own or lease. Additionally, in the future our facilities and the disposal sites owned by others to which we send or sent waste, may be identified as contaminated and require remediation. Accordingly, we may become subject to additional compliance costs or environmental liabilities which may be significant and could materially harm our results of operations or financial condition.

We are subject to existing and potential additional regulation and government inquiry, which can impose burdens on our operations and narrow the markets for our products.

We are subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of our operations and markets. For example, the exportation of our products is subject to U.S. and non-U.S. export control, sanctions, customs, import and anti-boycott laws and regulations, including, as applicable, the International Traffic in Arms Regulations, the Export Administration Regulations and the sanctions laws, regulations and executive orders administered and enforced by the U.S. Department of the Treasury’s Office of Foreign Assets Control, and other laws and regulations adopted by the governments or agencies of other countries relating to the same subject matter as the U.S. laws and regulations described above.

The failure to satisfy export control criteria or obtain necessary clearances could delay or prevent shipment of products, which could adversely affect our revenues and profitability. Failure by us, our employees or others working on our behalf to comply with these laws and regulations could result in administrative, civil or criminal liabilities, including suspension, debarment from bidding for or performing government contracts, or suspension of our export privileges, which could have a material adverse effect on us. We frequently team with international subcontractors and suppliers who are also exposed to similar risks. In some cases, compliance with the laws and regulations of one country could violate the laws and regulations of another country. Violations of these laws and regulations could materially adversely affect our brand, international growth efforts and business.

In addition, as a result of our international operations, we are subject to compliance with various laws and regulations, including the FCPA and local anti-bribery laws in the jurisdictions in which we do business (including some higher risk countries according to the Transparency International Corruption Index), which generally prohibit companies and their intermediaries or agents from engaging in bribery or making improper payments to foreign officials or their agents. The FCPA also requires proper record keeping and characterization of such payments in our reports filed with the SEC. Despite maintaining policies and procedures that require our employees to comply with these laws and our standards of ethical conduct, we cannot ensure that these policies and procedures will always protect us from intentional, reckless or negligent acts committed by our employees or third-party agents.

Moreover, the life sciences industry, which is the market for our principal products, has historically been heavily regulated. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulation that adversely affects our market opportunities. Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life sciences industry in particular.

35

Table of Contents

Our products are subject to the FDA’s requirements for electronic radiation emitting products, which include requirements related to record-keeping and reporting; labeling; notification; product repairs, replacements, and refunds; importation; and performance standards. In addition, our clinical products are subject to regulation as medical devices by the FDA in the United States and by similar regulatory bodies in other countries where such products are sold. These regulations govern a wide variety of product related activities, from quality management, design, development, and testing to labeling, manufacturing, complaint handling, reporting, promotion, sales and distribution. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA and other regulatory authorities, which may result in written inspectional observations. The FDA and comparable foreign regulatory authorities also monitor product promotion and marketing materials and activities. If we or any of our suppliers or distributors fail to comply with FDA or other applicable regulatory requirements, or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity affecting both us and our customers; investigations or notices of non-compliance, fines, injunctions, and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell such products. Any such FDA or comparable foreign regulatory actions could disrupt our business and operations, lead to significant remedial costs and have a material adverse impact on our financial position and results of operations. In addition, negative publicity and product liability claims resulting from any adverse regulatory action could have a material, adverse effect on our financial condition and results of operations. There are similar foreign regulations. For instance, the coming into force of the European Union Directive in May 2022 by the IVD Regulation (EU) 2017/746 imposes a stricter regime on manufacturers of IVDs and our products currently approved under the Directive must be recertified under the Regulation by May 2024.

We have been, are, and expect to be in the future, subject to inquiries from the government agencies that enforce these regulations, including the U.S. Department of State, the U.S. Department of Commerce, the U.S. FDA, the U.S. Internal Revenue Service, the U.S. Department of Homeland Security, the U.S. Department of Justice, the Securities and Exchange Commission, the Federal Trade Commission, U.S. Customs and Border Protection and the U.S. Department of Defense, among others, as well as from state or foreign governments and their departments and agencies. As a result, from time to time, the attention of our management and other resources may be diverted to attend to these inquiries. In addition, failure to comply with these regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenues and could adversely affect our financial condition and results of operations.

36

Table of Contents

We operate as an entrepreneurial, decentralized company, which presents both benefits and certain risks. In particular, significant growth in a decentralized operating model may put strain on certain business group resources and our corporate functions, which could materially and adversely affect our business, financial condition and results of operations

Decentralization necessarily places significant control and decision-making powers in the hands of local management, which presents certain risks, including the risk that we may be slower to detect or react to compliance-related matters and that “company-wide” business initiatives may be more challenging or costly to implement, and the risk of noncompliance or failures higher than they may be in a more centralized operating environment. In addition, key business group resources and our corporate functions, which are leanly staffed but responsible for supporting our decentralized operations, may also not be able to detect or resolve financial, operational, and compliance matters on a timely basis. Our failure to adapt our financial, operational and compliance controls and systems to effectively manage our decentralized business and comply with our obligations as a public company could materially and adversely affect our business, financial condition or results of operations.

General Risks Factors

If we are not able to successfully integrate the businesses we acquire through mergers, acquisitions or strategic alliances, we may not be able to realize all of the cost savings and other benefits that we expect to result from the transactions and our financial results may be different than expected.

Our strategy includes expanding our technology base and product offerings through selected mergers, acquisitions and strategic alliances. For example, from January 1, 2018 to December 31, 2020, we have acquired 13 businesses to expand our technologies and product offerings.

Successful integration of the businesses we acquire involves a number of risks, including, among others, risks related to:

coordinating or consolidating geographically separate organizations and integrating personnel with different business backgrounds and corporate cultures;
integrating previously autonomous departments in sales and marketing, distribution, accounting and administrative functions;
integrating financial information and management systems;
the pace of our acquisition activity and the related diversion of already limited resources and management time;
disruption of our ongoing business;
potential impairment of relationships with customers as a result of changes in management or otherwise arising out of such transactions; and
retention of key employees of the acquired businesses within the first one to two years after the acquisition, including the risk that they may compete with us subsequently.

37

Table of Contents

We may have difficulty developing, manufacturing and marketing the products of a newly acquired company or business in a way that enhances the performance of our combined businesses or product lines. As a result, we may not realize the value from expected synergies. Acquisitions have resulted, and may in the future result, in unexpected significant costs and expenses, including disputes over contingent consideration and complicated accounting for complex transaction structures. In the future, we may be required to record charges to earnings during the period if we determine there is an impairment of goodwill or intangible assets, up to the full amount of the value of the assets.

We generally assume the liabilities of businesses we acquire, which could include liability for an acquired business’ violation of law that occurred before we acquired it. In addition, we have historically acquired smaller, privately held companies that may not have strong cultures of legal compliance or the robust financial controls of a larger, publicly traded company, and if we fail to implement adequate training, controls, and monitoring of the acquired companies, we could also be liable for post-acquisition legal or accounting violations.

Other companies may have difficulty acquiring us, even if doing so would benefit our stockholders, due to provisions under our corporate charter and bylaws, as well as Delaware law.

Provisions in our certificate of incorporation, as amended, and our bylaws, as well as Delaware law could make it more difficult for other companies to acquire us, even if doing so would benefit our stockholders. Our certificate of incorporation, as amended, and bylaws contain the following provisions, among others, which may inhibit an acquisition of our company by a third party:

a staggered Board of Directors, where stockholders elect only a minority of the board each year;
advance notification procedures for matters to be brought before stockholder meetings;
a limitation on who may call stockholder meetings; and
the ability of our Board of Directors to issue up to 5,000,000 shares of preferred stock without a stockholder vote.

ITEM 1B   UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2   PROPERTIES

We believe that our existing principal facilities are well maintained and in good operating condition and that they are adequate for our foreseeable business needs.

In addition to the principal facilities noted below, we lease additional facilities for sales, applications and service support in various countries throughout the world including Australia, Austria, Belgium, Brazil, China, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Kenya, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, the United Kingdom and the United States. If we should require additional or alternative facilities, we believe that such facilities can be obtained on short notice at competitive rates.

38

Table of Contents

The location and general character of our principal properties are as follows:

    

    

Approximate

    

Square

Location

Principal Use

Feet

Relationship

Principal Facilities Used in Current Operations for Bruker Biospin:

 

  

 

  

 

  

Rheinstetten, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

475,000

 

Owned

Ettlingen, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

360,000

 

Owned

Faellanden, Switzerland

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

422,000
112,000

 

Owned
Leased

Wisemborg, France

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

189,000

 

Owned

Principal Facilities Used in Current Operations for Bruker CALID:

 

  

 

  

 

  

Bremen, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

270,000

 

Owned

Ettlingen, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

182,000

 

Owned

Nehren, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

87,000

 

Leased

Principal Facilities Used in Current Operations for BSI NANO:

 

  

 

  

 

  

Karlsruhe, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

145,000

 

Owned

Berlin, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

243,000

 

Owned

Santa Barbara, CA, U.S.A.

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

100,000

 

Owned

Graz, Austria

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

30,000

 

Leased

Penang, Malaysia

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

100,000

 

Leased

Migdal Ha’Emek, Israel

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

22,000

 

Leased

Principal Facilities Used in Current Operations for BEST:

 

  

 

  

 

  

Perth, Scotland

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

47,000

 

Owned

Hanau, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

138,000

 

Leased

Bergisch Gladbach, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

127,000

 

Leased

Carteret, NJ, U.S.A.

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

115,000

 

Leased

Alzenau, Germany

 

Manufacturing, Research and Development, Application and Demonstration, Marketing, Sales and Administrative

 

35,000

 

Leased

ITEM 3   LEGAL PROCEEDINGS

We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent and commercial matters, which arise in the ordinary course of business. There are no such matters pending that we currently believe are reasonably likely to have a material impact on our business or to our consolidated financial statements.

Details on recent legal matters can be found in Note 17 to our consolidated financial statements included in this Annual Report on Form 10-K under Item 8.

39

Table of Contents

In addition, we are subject to regulation by national, state and local government agencies in the United States and other countries in which we operate. From time to time, we are the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on our financial position, results of operations and/or liquidity.

ITEM 4   MINE SAFETY DISCLOSURES

Not applicable.

40

Table of Contents

PART II

ITEM 5   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Prices

Our common stock is traded on the Nasdaq Global Select Market under the symbol “BRKR.”

As of February 17, 2021, there were approximately 99 holders of record of our common stock. This number does not include individual beneficial owners of shares held in nominee name or within clearinghouse positions of brokerage firms and banks.

Dividends

In February 2016, we announced the establishment of a dividend policy and the declaration by our Board of Directors of an initial quarterly cash dividend in the amount of $0.04 per share of our issued and outstanding common stock. Future dividend payments, if any, are subject to approval of our Board of Directors. We are targeting a cash dividend to our shareholders in the amount of $0.16 per share per annum, payable in equal quarterly installments.

Stock Price Performance Graph

The graph below shows the cumulative stockholder return, assuming the investment of $100 (and the reinvestment of any dividends thereafter) for the period beginning on December 31, 2015 through December 31, 2020, for our common stock, stocks traded on Nasdaq, and a peer group consisting of U.S. public companies with a Standard Industry Classification, or SIC, code 3826 Laboratory Analytical Instruments. Such returns are based on historical results and are not intended to suggest future performance.

Graphic

41

Table of Contents

Cumulative Total Return Index for:

    

2015

    

2016

    

2017

    

2018

    

2019

    

2020

Bruker Corporation

$

100.0

$

87.84

$

143.14

$

124.79

$

214.45

$

228.55

Nasdaq Stock Market (US companies)

 

100.0

 

109.80

 

141.97

 

139.65

 

190.07

 

273.58

SIC Code 3826 Laboratory Analytical Instruments

 

100.0

 

94.46

 

145.07

 

152.36

 

190.81

 

252.10

The data for this performance graph was compiled by Zack’s Investment Research, Inc. and is used with its permission.

Issuer Purchases of Securities

The following table provides information about purchases made by or on behalf of the Company or any “affiliated purchaser,” as defined in Rule 10b-18(a)(3) under the Exchange Act, during the quarter ended December 31, 2020 of shares of our common stock.

Total Number of

Maximum Number (or

Shares Purchased as

Approximate Dollar Value) of

Total Number of

Part of Publicly

Shares that May Yet Be

Shares Purchased

Average Price

Announced Plans or

Purchased Under the Plans

Period

(1)

Paid per Share

Programs

or Programs (2)

October 1 - October 31, 2020

    

120,036

    

$

41.65

    

120,036

    

$

97,695,588

November 1 - November 30, 2020

722,838

$

48.39

722,838

$

62,715,823

December 1 - December 31, 2020

 

527,518

$

53.58

 

527,518

$

34,453,095

 

1,370,392

$

49.80

 

1,370,392

$

34,453,095

(1)The Company purchased shares of common stock in accordance with its share repurchase program approved by the Board of Directors and announced on May 10, 2019. The shares were purchased on the open market at prevailing prices.
(2)The Repurchase Program authorizes the Company to purchase up to $300.0 million of its common stock over a two-year period. The Repurchase Program expires May 13, 2021 and can be suspended, modified or terminated at any time without prior notice. Purchases of common stock may occur from time to time, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements and other considerations. At February 25, 2021, $5.3 million remains for future purchase under the share purchase program.

In 2020, we repurchased 2,711,952 shares of common stock with an aggregate cost of approximately $123.2 million under the 2019 Repurchase Program. Any future repurchases will be funded from cash on hand, future cash flows from operations and available borrowings under our revolving credit facility.

ITEM 6     RESERVED

42

Table of Contents

ITEM 7   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and notes to those statements, appearing elsewhere in this report. This report contains forward-looking statements reflecting our current expectations that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. The cautionary statements made in this report should be read as applying to all related forward-looking statements wherever they appear in this report. Our actual results may differ materially from those indicated in the forward-looking statements due to a number of factors, including those discussed in Item 1A, Risk Factors and elsewhere in this report.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, describes the principal factors affecting the results of our operations, financial condition and changes in financial condition, as well as our critical accounting policies and estimates. Our MD&A is organized as follows:

Non-GAAP Measures. This section provides appropriate disclosures regarding forward looking statements and our use of Non-GAAP financial measures.
Overview. This section provides a brief discussion of our reportable segments’ results of operations, significant recent developments in our businesses, and challenges and risks that may impact our businesses in the future.
Results of Operations. This section provides our analysis of the significant line items on our consolidated statements of income and comprehensive income (loss) for the year ended December 31, 2020 compared to the year ended December 31, 2019 and for the year ended December 31, 2019 compared to the year ended December 31, 2018.
Liquidity and Capital Resources. This section provides an analysis of our liquidity and cash flow and a discussion of our outstanding debt and commitments.
Critical Accounting Policies and Estimates. This section discusses the accounting estimates that are considered important to our financial condition and results of operations and require us to exercise subjective or complex judgments in their application. All of our significant accounting policies are summarized in Note 2 to our consolidated financial statements in Item 8 of this Annual Report on Form 10-K.
Recent Accounting Pronouncements. This section provides a summary of recent accounting pronouncements and discusses their potential impact on our consolidated financial statements.

Non-GAAP Measures

Although our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), we believe describing revenue and expenses, excluding the effects of foreign currency, acquisitions and divestitures, as well as certain other charges, net, provides meaningful supplemental information regarding our performance. We rely internally on certain measures that are not calculated according to GAAP. These measures are organic revenue, free cash flow, non-GAAP gross profit margin and non-GAAP operating margin. Our management believes that these financial measures provide relevant and useful information that is widely used by equity analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. We define the term organic revenue as GAAP revenue excluding the effect of foreign currency translation changes and the effect of acquisitions and divestitures. We define the term non-GAAP gross profit margin as GAAP gross profit margin with certain non-GAAP measures excluded and non-GAAP operating margin as GAAP operating margin with certain non-GAAP measures excluded. These non-GAAP measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of

43

Table of Contents

acquired intangible assets, costs associated with our global information technology transition initiative, and other non-operational costs and we believe these are useful measures to evaluate our continuing business.

We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends and repayment of debt. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities. These measures may also be useful to investors in evaluating the underlying operating performance of our business. The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.

OVERVIEW

We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, Asia and North America, we have sales offices located throughout the world. Bruker is organized into three reportable segments: the BSI Life Science Segment (comprised of the Bruker BioSpin Group and the Bruker CALID Group), the BSI NANO Segment and the Bruker Energy & Supercon Technologies (BEST) Segment.

Revenue for the year ended December 31, 2020 decreased by $85.1 million, or 4.1%, to $1,987.5 million, compared to $2,072.6 million for the comparable period in 2019. The decline in revenue was primarily related to the impact of the COVID-19 pandemic and the related economic slowdown. Included in revenue were increases of approximately $29.4 million in favorable impact of foreign currency translation and $10.5 million attributable to our recent acquisitions in the year ended December 31, 2020 compared to the year ended December 31, 2019. Excluding the effects of foreign currency translation and recent acquisitions, our organic revenue, a non-GAAP measure, decreased by $125.0 million, or 6.0%.

Our gross profit margin decreased to 47.3% for the year ended December 31, 2020 as compared to 48.0% during the year ended December 31, 2019. The decrease in gross margin was a result of lower volume and reduced productivity due to disruptions from the COVID-19 pandemic and the related economic slowdown, partially offset by certain cost reduction measures.

Our operating margin decreased to 12.5% for the year ended December 31, 2020 from 14.5% during the year ended December 31, 2019. The decrease in operating margin was due to lower revenue and gross profit during the COVID-19 pandemic and related economic slowdown, partially offset by cost control and cost reduction measures.

The income tax provision in the years ended December 31, 2020 and December 31, 2019 was $64.4 million and $82.4 million, respectively, representing effective tax rates of 28.5% and 29.4%, respectively. The decrease in our effective tax rate for the year ended December 31, 2020, compared to 2019, was primarily attributable to the change in jurisdictional income mix and decrease in foreign income inclusions due to electing the high tax exemption relating to Global Intangible Low-Taxed Income (“GILTI”), partially offset by an increase in the effective tax rate due to change in valuation allowance. Our tax rate may change over time as the amount and mix of jurisdictional income mix changes.

44

Table of Contents

Earnings per share decreased to $1.02 per diluted share for the year ended December 31, 2020 from $1.26 per diluted share for the year ended December 31, 2019. The decrease compared to the prior year was driven primarily by lower revenues during the COVID-19 pandemic and related economic slowdown, partially offset by our cost control and cost reduction measures.

The following table presents a reconciliation from net cash provided by operating activities, which is the most directly comparable GAAP operating financial measure, to free cash flow as used by management (in millions):

 

Year Ended December 31,

2020

    

2019

    

2018

Net cash provided by operating activities

$

332.2

$

213.4

$

239.7

Less: purchases of property, plant and equipment

 

97.2

 

73.0

 

49.2

Free Cash Flow

$

235.0

$

140.4

$

190.5

For the year ended December 31, 2020, our free cash flow was 67% higher than the same period in 2019, primarily from an increase in customer advances and cash from receivables despite a decline in net income.

The following table presents a reconciliation from gross profit, which is the most directly comparable GAAP operating performance measure, to non-GAAP gross profit margin as used by management (in millions):

Year Ended December 31,

2020

2019

2018

Gross profit

    

$

939.8

    

$

995.3

    

$

900.0

Restructuring costs

    

 

3.8

 

5.2

 

2.6

Acquisition-related costs

    

 

0.8

 

12.2

 

3.9

Purchased intangible amortization

    

 

19.9

 

23.5

 

21.6

Other costs

    

 

3.7

 

0.8

 

0.6

Non-GAAP gross profit margin

    

$

968.0

$

1,037.0

$

928.7

Our non-GAAP gross profit margin was 48.7%, 50.0% and 49.0% in the years ended December 31, 2020, 2019 and 2018, respectively. Our non-GAAP gross profit margin decreased in 2020, as compared to 2019 due to lower volume and reduced productivity, due to COVID-19 and the economic slowdown. Our non-GAAP gross profit margin increased in the year ended December 31, 2019, as compared to the same period in 2018, primarily due to operational improvements within our BSI Life Science Segment, accretive acquisitions and favorable foreign currency translation effects.

The following table presents a reconciliation from operating income, which is the most directly comparable GAAP operating performance measure, to non-GAAP operating income as used by management (in millions):

Year Ended December 31,

2020

2019

2018

Operating income

    

$

248.3

    

$

300.9

    

$

262.4

Restructuring costs

 

15.8

 

1.4

 

9.4

Acquisition-related costs

 

3.2

 

16.8

 

7.3

Purchased intangible amortization

 

35.7

 

38.3

 

28.9

Other costs

 

14.2

 

6.6

 

9.9

Non-GAAP operating margin

$

317.2

$

364.0

$

317.9

45

Table of Contents

Our non-GAAP operating margin was 16.0%, 17.6% and 16.8% in the years ended December 31, 2020, 2019 and 2018, respectively. Our non-GAAP operating margin decreased in 2020, as compared to 2019 on lower revenues, partially offset by cost control and cost reduction measures.

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

the impact of the COVID-19 global pandemic on our customers, supply chain or manufacturing capabilities;
the timing of governmental stimulus programs and academic research budgets;
the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received;
foreign currency exchange rates;
the time it takes for us to receive critical materials to manufacture our products;
general economic conditions, including the impact of COVID-19 on the global economy;
the time it takes to satisfy local customs requirements and other export/import requirements;
the time it takes for customers to construct or prepare their facilities for our products; and
the time required to obtain governmental licenses.

Several of these factors have in the past affected the amount and timing of revenue recognized on sales of our products and receipt of related payments and will continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance. The COVID-19 pandemic continues to present a challenging operating environment and we remain focused on four key priorities: the health and safety of our employees, customers and partners; maintaining business continuity and service levels for our customers; executing prudent temporary cost reductions; and delivering enabling research and diagnostic products to help fight the pandemic, and to support other essential priorities of our society.

Health and safety of our valued employees, customers and partners

While Bruker's businesses are essential, we have implemented strict social distancing, enhanced cleaning protocols and other preventative measures, such as temperature scanners and company-issued face coverings, in our major facilities. While many of our office colleagues are working remotely, we are placing enhanced focus on our service organization and factory employees for whom work from home is not feasible. Where customer sites are accessible and open, our field service organizations operate under social distancing protocols to ensure the safety of customer sites, when our employees need to be on site.

46

Table of Contents

Maintaining business continuity and service levels for our customers

Ensuring our ability to supply our enabling technologies and solutions and maintaining high service levels for our customers is another top priority for Bruker. In late March and during parts of April 2020, several of our manufacturing sites underwent temporary controlled shutdowns or were operating at reduced capacity to implement new safety protocols, comply with local rules, and manage cost and inventory levels. These sites thereafter ramped back up with expanding capacity and productivity levels. However, with any resurgence of the virus or the emergency of additional strains of the virus, we may need to consider further temporary controlled shutdowns or reduced capacity measures. In addition, we are continuing capital investments in production facilities for efficiencies and expansion and our supply chain remains resilient. We carry higher inventory levels to address supply chain risks related to the pandemic and do not currently anticipate being supply or capacity limited in the first quarter of 2021.

Executing prudent temporary cost reductions

In an effort to mitigate the negative impacts on our business of COVID-19, and the slowdown in the global economy, we implemented temporary cost control and cost reduction measures. These temporary measures included short-time work for many of our European operations, temporary tiered salary reductions for our board of directors, global leadership team and workforce, one-to two-week closures of select manufacturing locations, selective product manufacturing reductions, a hiring freeze, and curtailment of non-strategic discretionary spending. At the same time, we looked to minimize the disruption for our employees and preserve our ability to ramp up again with our highly trained and loyal work force. While pursuing cost savings throughout the business, we have maintained our important investments in key strategic initiatives. Many of the cost reduction measures have now been relaxed and our revenue is experiencing a recovery.

Delivering enabling research and diagnostic products to help fight the pandemic and to support other essential priorities of our society

Bruker is providing critical technologies and solutions to help combat the COVID-19 crisis, most notably our Microbiology and infectious disease diagnostics portfolio, to which we have added SARS-COV-2 PCR tests, and our nuclear magnetic resonance and mass spectrometry systems which are used in critical disease, therapeutic and vaccine research.

The COVID-19 global pandemic has driven volatility and uncertainty in global markets and has affected our operations significantly. We continue to work to manage the impact of COVID-19 on our operations; however, the full extent to which any resurgence of the virus or the emergence of any new strains of the virus will impact our business, directly or indirectly, cannot accurately be predicted at this time. In 2020, the COVID-19 pandemic affected productivity at our manufacturing facilities and caused disruptions and delays in certain of our shipments to customers who closed facilities during the pandemic. We continue to monitor the impact of COVID-19 on our business and respond accordingly. For additional information on the various risks posed by the COVID-19 pandemic, refer to Item 1A. Risk Factors included in this report.

47

Table of Contents

RESULTS OF OPERATIONS

Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019

Consolidated Results

The following table presents our results for the years ended December 31, 2020 and 2019 (in millions, except per share data):

Year Ended

December 31, 

Percentage

    

2020

    

2019

    

Dollar Change

    

Change

Product revenue

$

1,638.1

$

1,744.7

$

(106.6)

(6.1)

%

Service revenue

 

343.4

 

322.4

 

21.0

 

6.5

Other revenue

 

6.0

 

5.5

 

0.5

 

9.1

Total revenue

 

1,987.5

 

2,072.6

 

(85.1)

 

(4.1)

Cost of product revenue

 

840.2

 

878.5

 

(38.3)

 

(4.4)

Cost of service revenue

 

206.5

 

198.3

 

8.2

 

4.1

Cost of other revenue

 

1.0

 

0.5

 

0.5

 

100.0

Total cost of revenue

 

1,047.7

 

1,077.3

 

(29.6)

 

(2.7)

Gross profit

 

939.8

 

995.3

 

(55.5)

 

(5.6)

Operating expenses:

 

 

 

 

Selling, general and administrative

 

468.6

 

500.2

 

(31.6)

 

(6.3)

Research and development

 

198.0

 

187.7

 

10.3

 

5.5

Other charges, net

 

24.9

 

6.5

 

18.4

 

283.1

Total operating expenses

 

691.5

 

694.4

 

(2.9)

 

(0.4)

Operating income

 

248.3

 

300.9

 

(52.6)

 

(17.5)

Interest and other income (expense), net

 

(22.5)

 

(20.5)

 

(2.0)

 

9.8

Income before income taxes and noncontrolling interest in consolidated subsidiaries

 

225.8

 

280.4

 

(54.6)

 

(19.5)

Income tax provision

 

64.4

 

82.4

 

(18.0)

 

(21.8)

Consolidated net income

 

161.4

 

198.0

 

(36.6)

 

(18.5)

Net income attributable to noncontrolling interest in consolidated subsidiaries

 

3.6

 

0.8

 

2.8

 

350.0

Net income attributable to Bruker Corporation

$

157.8

$

197.2

$

(39.4)

(20.0)

%

Net income per common share attributable to

 

  

 

  

 

  

 

  

Bruker Corporation shareholders:

 

  

 

  

 

  

 

  

Basic

$

1.03

$

1.27

$

(0.24)

(18.9)

%

Diluted

$

1.02

$

1.26

$

(0.24)

(19.0)

%

Weighted average common shares outstanding:

 

  

 

  

Basic

 

153.4

 

155.2

Diluted

 

154.6

 

156.6

Revenue

The decline in revenue was primarily related to the impact of the COVID-19 pandemic on our customers as well as certain of our operations and lower global instrumentation and superconductor demand due to the pandemic and related economic slowdown.

Gross Profit

The decline in gross profit was a result of lower revenue volume and reduced productivity, given the impact of the pandemic and economic slowdown, partially offset by cost control and cost reduction measures.

48

Table of Contents

Selling, General and Administrative

Our selling, general and administrative expenses in year ended December 31, 2020 decreased to 23.6% of total revenue from 24.1% of total revenue for the comparable period in 2019. The decrease as a percentage of total revenue, and in dollars, was a result of the cost control and cost reduction measures implemented during the COVID-19 pandemic in 2020.

Research and Development

Our research and development expenses for the year ended December 31, 2020 increased to 10.0% of total revenue from 9.1% of total revenue for the comparable period in 2019. The increase as a percentage of revenue, and in dollars, was a result of higher research and development spending, as we continued to fund certain growth investments, in comparison to lower revenue in 2020.

Other Charges, Net

Other charges, net was $24.9 million for the year ended December 31, 2020. The charges consisted primarily of $12.0 million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives, $5.9 million related to professional fees, $2.5 million of costs associated with our global IT transformation initiative, $2.4 million of acquisition-related charges related to acquisitions completed in 2020 and 2019 and $2.1 million related to long-lived asset impairments.

Other charges, net was $6.5 million for the year ended December 31, 2019. The charges consisted primarily of $(3.9) million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives, $4.6 million of acquisition-related charges related to acquisitions completed in 2019 and 2018, $3.7 million of costs associated with our global IT transformation initiative, and $2.1 million related to professional fees. The restructuring charges included a gain on the sale of a building of $7.7 million.

Operating Income

The decrease in operating income was due to lower revenue and gross profit during the COVID-19 pandemic and related economic slowdown, partially offset by cost control and cost reduction measures.

Interest and Other Income (Expense), Net

The primary components within interest and other income (expense), net for the year ended December 31, 2020 were net interest expense of $11.2 million, realized and unrealized losses on foreign currency denominated transactions of $8.0 million and $3.3 million related to pension plan. During the year ended December 31, 2019, the primary components were net interest expense of $14.7 million, realized and unrealized losses on foreign currency denominated transactions of $3.4 million, $2.5 million related to pension plan expenses and $0.1 million related to other income.

Income Tax Provision

The effective tax rates for years ended 2020 and 2019 were 28.5% and 29.4%, respectively. The decrease in our effective tax rate for the year ended December 31, 2020, compared to 2019, was primarily attributable to the change in jurisdictional income mix and decrease in foreign income inclusions due to electing the high tax exemption relating to GILTI, partially offset by an increase in the effective tax rate due to change in valuation allowance. Our tax rate may change over time as the amount and mix of jurisdictional income changes.

Net Income Attributable to Noncontrolling Interests and Redeemable Noncontrolling Interest

The net income attributable to noncontrolling interests represented the minority shareholders' proportionate share of the net income recorded by our majority-owned subsidiaries. In January 2020, we acquired the remaining interest in our redeemable noncontrolling interest.

49

Table of Contents

Net Income Attributable to Bruker Corporation

The decrease in net income and earnings per diluted share was primarily driven by the decline in revenue, gross profit and operating profit as a result of reduced demand during the COVID-19 pandemic and the related economic slowdown.

Segment Results

Revenue

The following table presents revenue, change in revenue, and revenue growth by reportable segment for the years ended December 31, 2020 and 2019 (dollars in millions):

    

    

    

    

Percentage 

 

2020

2019

Dollar Change

Change

BSI Life Science

$

1,253.9

$

1,244.9

$

9.0

 

0.7

%

BSI Nano

556.1

632.7

(76.6)

(12.1)

BEST

 

189.5

 

209.9

 

(20.4)

 

(9.7)

Eliminations (a)

 

(12.0)

 

(14.9)

 

2.9

 

$

1,987.5

$

2,072.6

$

(85.1)

 

(4.1)

%

(a)Represents product and service revenue between reportable segments.

For financial reporting purposes, we aggregate Bruker BioSpin Group and Bruker CALID Group as the BSI Life Science Segment. This aggregation reflects the similar economic characteristics, production processes, customer services provided, types and classes of customers, methods of distribution and regulatory environments.

BSI Life Science Segment revenue was approximately flat year over year from a decline in BioSpin systems and FTIR/NIR molecular spectroscopy revenues, due to the COVID-19 pandemic, which was offset by strong demand for our CALID microbiology and infectious disease diagnostics offering and for certain of CALID’s mass spectrometry systems. The decline in revenues for the BSI NANO Segment was due primarily to the impact of the COVID-19 pandemic and the related economic slowdown with reduced academic, industrial and industrial research demand. The decline in revenue for the BEST Segment was due to lower superconductor demand during 2020.

Operating Income

The following table presents operating income and operating margins on revenue by reportable segment for the years ended December 31, 2020 and 2019 (dollars in millions):

2020

2019

Percentage of

Percentage of

 

Operating

Segment

Operating

Segment

    

Income

    

Revenue

    

Income

    

Revenue

 

BSI Life Science

$

273.8